艾尔巴韦/格拉瑞韦(Elbasvir/Grazoprevir) - 药物靶点：NS3/NS4A x NS5A_在研适应症：丙型肝炎，慢性丙型肝炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Elbasvir and grazoprevir、Elbasvir/Grazoprevir Hydrate、Grazoprevir/elbasvir

+ [6]

靶点

NS3/NS4A x NS5A

作用方式

抑制剂

作用机制

NS3/NS4A抑制剂(丙型肝炎病毒NS3/NS4A丝氨酸蛋白酶抑制剂)、NS5A抑制剂(非结构蛋白5A抑制剂)

治疗领域

感染消化系统疾病

在研适应症

丙型肝炎慢性丙型肝炎

非在研适应症

慢性丙型肝炎基因型 1慢性丙型肝炎基因型 3纤维化+ [5]

原研机构

Merck Sharp & Dohme Corp.

在研机构

Merck Sharp & Dohme BVMerck GmbH

Merck Canada, Inc.

非在研机构

Merck Sharp & Dohme Corp.

权益机构-

最高研发阶段批准上市

首次获批日期

加拿大 (2016-01-19),

慢性丙型肝炎

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)、特殊审批 (中国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C49H55N9O7

InChIKeyBVAZQCUMNICBAQ-PZHYSIFUSA-N

CAS号1370468-36-2

查看全部结构式(2)

关联

62

项与艾尔巴韦/格拉瑞韦相关的临床试验

NCT03381859

/ Withdrawn临床4期IIT

A Single-site, Open-label, Non-comparator Clinical Trial to eLiminate HCV-infection in Treatment-naïve, EgyptiAn Patients With End-stage Renal Disease on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Infection Using a 12-week Course of Once-daily Single Oral Tablet of Elbasvir (50mg)/Grazoprevir (100 mg)

Primary Efficacy Objective
-To assess whether a 12-week treatment course with oral 50 mg elbasvir plus 100 mg grazoprevir given in a single daily dose to treatment-naïve patients with end-stage renal disease (ESRD) and infected with genotype 4 (GT4) chronic HCV (CHC) infection can produce a sustained viral response (SVR), i.e. HCV RNA below the lower limit of quantification [LLOQ] for 12 weeks (SVR12) after completion of the study treatment course
Secondary Objectives
* To assess the efficacy of elbasvir/grazoprevir in suppressing HCV viremia in treatment-naïve GT4 CHC patients at each scheduled visit and clinically meaningful endpoints (Week 2, 8 and 12 [End of Treatment - EOT]) and 24 (SVR12)
* To assess the safety and tolerability of a 12-week treatment course with elbasvir/grazoprevir in treatment-naïve patients with ESRD and infected with GT4 CHC.
* To assess liver fibrosis by non-invasive evaluation of liver stiffness (Fibroscan®) in the same patients before treatment and EOT and SVR12
Clinical hypotheses.
Primary Efficacy Hypothesis
- A 12-week treatment course with elbasvir/grazoprevir in treatment-naïve patients with ESRD and infected with GT4 CHC infection will result in an HCV RNA below the LLOQ in 95% of patients within 2 weeks of treatment, and at least 95% will have an SVR12.
Secondary hypotheses
* A 12-week treatment course with elbasvir/grazoprevir in ESRD GT4 treatment-naïve patients will result in undetectable viremia in 95% patients at Week 2, 4, 8 and 12 (EOT) and 24 (SVR12)
* Treatment will be safe and well-tolerated in these patients, as determined by the type and number of adverse events identified through laboratory testing, vital signs and physical examinations.
* In these patients with liver fibrosis before treatment, the liver fibrosis as assessed by non-invasive evaluation of liver stiffness (Fibroscan®) will improve by EOT and SVR12

开始日期2019-12-01

申办/合作机构

University of Maryland Baltimore

[+2]

NCT03365635

/ Completed临床4期IIT

"Real World" Administration of Zepatier (Grazoprevir Plus Elvasvir) in Chronic Hemodialysis Patients With Hepatitis C Infection. Strategies for Identification of Patients, Insurance Approval, Treatment , and Laboratory Monitoring

This is a study to define strategies for Nephrologists to directly supervise and apply direct acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include identification of candidate patients, application for insurance approval, specifics of direct acting antiviral therapy (Zepatier with or without ribavirin) and laboratory monitoring during and after therapy.

开始日期2019-09-22

申办/合作机构

University of Pennsylvania

[+1]

NCT04048850

/ CompletedN/AIIT

Cohort Study of Hepatitis C Virus Treatment with Zepatier (Elbasvir/Grazoprevir) in Genotype 1 or 4 HCV Treatment-Naïve or Peginterferon/Ribavirin-Experienced Patients with Substance Use in Urban, Multidisciplinary Specialty Clinics

The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use in urban, multidisciplinary specialty clinics.

开始日期2019-09-20

申办/合作机构

University of Illinois

[+1]

100 项与艾尔巴韦/格拉瑞韦相关的临床结果

登录后查看更多信息

100 项与艾尔巴韦/格拉瑞韦相关的转化医学

登录后查看更多信息

100 项与艾尔巴韦/格拉瑞韦相关的专利（医药）

登录后查看更多信息

37

项与艾尔巴韦/格拉瑞韦相关的文献（医药）

2023-03-04·Scandinavian journal of gastroenterology

High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway

Article

作者: Simonsen, Øystein ; Bergersen, Bente M. ; Singh, Ravinder ; Dalgard, Olav ; Hagen, Karin ; Roberts, R. Scott ; Mikkelsen, Yngve ; Lagging, Martin ; Finbråten, Ane-Kristine ; Rosseland, Carola M. ; Young, Lital ; Sandvei, Per Kristian ; Leiva, Rafael A.

BACKGROUND AND AIMS:

The recommended treatment duration of hepatitis C virus (HCV) genotype 1a (GT1a) infection with elbasvir/grazoprevir (EBR/GZR) in the presence of a high baseline viral load and resistance associated substitutions (RAS) is 16 weeks with ribavirin added. The objective of this study was to evaluate the real-world effectiveness of 12 weeks of EBR/GZR without ribavirin and regardless of baseline viral load and RAS testing.

METHOD:

This retrospective, observational cohort study was performed at five Norwegian hospitals that did not systematically utilize RAS testing. All adult patients with chronic HCV GT1a and compensated liver disease who had received 12 weeks of EBR/GZR without ribavirin and baseline RAS testing, were included. The primary endpoint was sustained virologic response at week 12 (SVR12), or if not available, at week 4 (SVR4).

RESULTS:

We included 433 patients and attained SVR data on 388. The mean age was 45.7 years (22-73 years). 67.2% were male. HIV co-infection was present in 3.8% (16/424) and cirrhosis in 4% (17/424). The viral load was >800 000 IU/mL in 55.0% (235/427) of patients. Overall SVR was achieved in 97.2% (377/388). SVR was achieved in 98.3% (169/172) of those with viral load ≤800 000 IU/mL and in 96.2% (202/210) of those with viral load >800 000 IU/mL.

CONCLUSION:

We observed high SVR rates among patients with HCV GT1a infection treated with EBR/GZR for 12 weeks without ribavirin, with no regard to baseline viral load and no RAS testing.

2022-10-01·Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Full-genome next-generation sequencing of hepatitis C virus to assess the accuracy of genotyping by the commercial assay LiPA and the prevalence of resistance-associated substitutions in a Belgian cohort

Article

作者: Vandamme, Anne-Mieke ; Simmonds, Peter ; Dierckx, Tim ; Beuselinck, Kurt ; Schrooten, Yoeri ; Bonsall, David ; Bowden, Rory ; Lagrou, Katrien ; Christensen, Kasper T ; Pierard, Florian ; Cuypers, Lize ; Van Laethem, Kristel ; Nevens, Frederik ; Van Wijngaerden, Eric

BACKGROUND:

Although most currently used regimens for Hepatitis C virus (HCV) infections can be initiated without prior knowledge of genotype and subtype, genotyping is still useful to identify patients who might benefit from a personalized treatment due to resistance to direct-acting antivirals (DAA).

OBJECTIVES:

To assess the utility of full-genome next-generation sequencing (FG-NGS) for HCV genotyping.

STUDY DESIGN:

138 HCV plasma samples previously genotyped by VERSANT HCV Genotype Assay (LiPA) were subjected to FG-NGS and phylogenetically genotyped Genome Detective. Consensuses were analysed by HCV-GLUE for resistance-associated substitutions (RASs) and their impact on treatment response was investigated.

RESULTS:

102/138 (73.9%) samples were sequenced to a genome coverage and depth of >90% of the HCV open reading frame covered by >100 reads/site. Concordant genotype and subtype results were assigned in 97.1% and 79.4% of samples, respectively. FG-NGS resolved the subtype of 13.7% samples that had ambiguous calls by LiPA and identified one dual infection and one recombinant strain. At least one RAS was found for the HCV genes NS3, NS5A, and NS5B in 2.91%, 36.98% and 27.3% samples, respectively. Irrespective of the observed RAS, all patients responded well to DAA treatment, except for HCV1b-infected patients treated with Zepatier (33.3% failure rate (5/15)).

CONCLUSION:

While LiPA and FG-NGS showed overall good concordance, FG-NGS improved specificity for subtypes, recombinant and mixed infections. FG-NGS enabled the detection of RAS, but its predictive value for treatment outcome in DAA-naïve patients remains uncertain. With additional refinements, FG-NGS may be the way forward for HCV genotyping.

2022-07-01·Dermatologic therapy

Cardiac conduction block during secukinumab treatment

Letter

作者: Tang, Xin ; Huang, Kun ; Zheng, Xuyu ; Hu, Li ; Wang, Ping ; Chen, Aijun

Psoriasis is an immune-mediated chronic inflammatory skin disease and IL-17A is a cornerstone of the pathogenesis of psoriasis.Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, is effective in treating moderate to severe psoriasis.This article reports a rare case of cardiac conduction block occurring during the treatment with secukinumab.A man in his 30s presented with moderate and severe psoriasis vulgaris, and the body surface area was above 30%.He was commenced on secukinumab therapy for psoriasis and Zepatier (elbasvir and grazoprevir) for hepatitis C.The treatment with secukinumab continued, and after 3 mo, the remission of all skin lesions was obtained and the patient frequently experienced dizziness, headache, and palpitation.In this case, some factors might relate to cardiac conduction block, such as underlying heart disease, hepatitis C, and drugs.Some cardiac disorders, as a rare adverse events, have been observed in the real-world clin. trials, including tachycardia, atrioventricular first-degree block, and sinus bradycardia.Thus, authors are still in the early stages of exploring the effect of secukinumab on the heart.

77

项与艾尔巴韦/格拉瑞韦相关的新闻（医药）

2026-10-10

·IDepi

IDepi · 传染病流行病学每日文献速递 1010｜HPV疫苗安全、青蒿素耐药、沙门菌跨国流调

IDepi · 传染病流行病学每日文献速递 · 2026-10-10（周六）数据来源：PubMed（近 3 天新收录，按数据库收录日而非论文发表日计）· 本期收录 449 篇今日看点今日按入选标准（人群水平流行病学研究）共监测到 449 篇新文献，编辑部按重要性、新颖性与多样性精选 7 篇深读：HPV 疫苗孕前接种的妊娠安全（瑞典 62 万例，BMJ）、赞比亚青蒿素耐药新突变 8 年从 0 升至 79%（Lancet ID）、216 例沙门菌疫情的跨国流调复盘（Euro Surveill）、孕期流感与子代神经精神的 274 万对母婴答案（JAMA Netw Open）、污水厂抗生素管控的工艺级风险地图（Water Res，浙大团队）、感染率调查数据导航的结核精准筛查（PLoS Med）、以及 33 年降 94% 的全球破伤风负担图景（GBD 2023）。分类看，新冠与冠状病毒文献居首（81 篇），HIV 与性传播疾病（67 篇）、虫媒与热带病（47 篇）分列二三。今日深读 · 编辑部精选 7 篇 1. Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study. BMJ（IF 42.7）· Zhang Z 等 · 10.1136/bmj-2026-100739（深读见今日推送） 2. Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study. Lancet Infect Dis（IF 29.4）· Mwenda M 等 · 10.1016/S1473-3099(26)00478-000478-0)（深读见今日推送） 3. A multi-country outbreak of Salmonella Blockley associated with tomato consumption, July to October 2024. Euro Surveill（IF 9.9）· Hoban A 等 · 10.2807/1560-7917.ES.2026.31.40.2500862（深读见今日推送） 4. Maternal Influenza Infection During Pregnancy and Neuropsychiatric Disorders in Offspring. JAMA Netw Open（IF 10.5）· Kong J 等 · 10.1001/jamanetworkopen.2026.37902（深读见今日推送） 5. A process-resolved risk prioritization framework reveals hidden antibiotic control deficiencies in wastewater treatment trains. Water Res（IF 11.4）· Lu X 等 · 10.1016/j.watres.2026.127080（深读见今日推送） 6. Potential health impacts and costs of active case finding guided by Mycobacterium tuberculosis immunoreactivity survey results in Blantyre, Malawi: A mathematical modeling study. PLoS Med（IF 11）· Kim S 等 · 10.1371/journal.pmed.1005272（深读见今日推送） 7. Global, regional, and national burden of tetanus in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. EClinicalMedicine（IF 9.6）· GBD 2023 Tetanus Collaborators 等 · 10.1016/j.eclinm.2026.104202（深读见今日推送）分类速览分类篇数新冠与冠状病毒81流感与其他呼吸道病毒26结核病15HIV与性传播疾病67虫媒与热带病47病毒性肝炎19疫苗与免疫策略29耐药与医院感染38新发与再现传染病23肠道与食源性疾病14监测预警与数学模型21其他69合计449 新冠与冠状病毒（81 篇） 1. Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus. 译：暴露途径而非剂量：呼吸道病毒感染模式的首要驱动因素 Sci Adv（IF 11.7） · Snedden CE 等 · 2026 10.1126/sciadv.aei4853 2. A Primary Care E-Health Family Intervention for Risk Behaviors in Hispanic Youths: A Randomized Clinical Trial. 译：西班牙裔青少年风险行为初级保健电子健康家庭干预随机试验 JAMA Netw Open（IF 10.5） · Estrada Y 等 · 2026 10.1001/jamanetworkopen.2026.37908 3. Assessing the impact of the COVID-19 pandemic on routine childhood vaccination uptake, the Netherlands, 2016 to 2025. 译：新冠大流行对荷兰常规儿童疫苗接种的影响（2016-2025） Euro Surveill（IF 9.9） · Pijpers J 等 · 2026 10.2807/1560-7917.ES.2026.31.40.2600159 4. Prospective cohort study for digital health research in Germany (DigiHero): objectives, design and baseline characteristics. 译：德国数字健康前瞻队列DigiHero：目标、设计与基线特征 Eur J Epidemiol（IF 8.3） · Klee B 等 · 2026 10.1007/s10654-026-01454-7 5. Influence of COVID-19 and COVID-19 rumours on trust and uptake of single-dose male HPV vaccination in the Add-Vacc cluster-randomised trial, northwest Tanzania. 译：新冠疫情与相关谣言对单剂男性HPV疫苗信任与接种的影响 Vaccine（IF 4.5） · Malibwa D 等 · 2026 10.1016/j.vaccine.2026.129231 6. Mobile-app-based cohort event monitoring study (CEM) of COVID-19 vaccines. 译：基于移动应用的新冠疫苗队列事件监测研究 Vaccine（IF 4.5） · Kopp L 等 · 2026 10.1016/j.vaccine.2026.129219 7. Mycoplasma pneumoniae infections in the Post-COVID era: recent advances from pathogenesis to clinical management. 译：新冠后时代的肺炎支原体感染：从病原学到流行病学的新进展 Infection（IF 3.9） · Li Y 等 · 2026 10.1007/s15010-026-02990-w 8. Association between the glucose-to-lymphocyte ratio and prognosis in COVID-19 patients. 译：葡萄糖-淋巴细胞比值与新冠患者预后的关联 Front Cell Infect Microbiol（IF 3.9） · Shi C 等 · 2026 10.3389/fcimb.2026.1881669 9. Microbial communities on station and train surfaces in Chennai Metro: insights into urban transit microbiome. 译：金奈地铁车站与列车表面微生物群落：城市交通微生物组洞察 mSphere（IF 3.3） · Singh VY 等 · 2026 10.1128/msphere.00433-26 10. Context-specific strategies for enhancing HPV vaccination: key informant perspectives from selected U.S. jurisdictions in the post-COVID-19 era. 译：提升HPV疫苗接种的情境化策略：关键知情人访谈 Front Public Health（IF 3） · Escabí-Wojna E 等 · 2026 10.3389/fpubh.2026.1810928 11. SARS-CoV-2 infection and two-year longitudinal clinical trajectory in pulmonary hypertension: a single-center retrospective exploratory cohort study. 译：新冠感染与肺动脉高压患者两年纵向临床轨迹 Front Public Health（IF 3） · Alqahtani A 等 · 2026 10.3389/fpubh.2026.1901917 12. COVID-19 vaccine compliance among pregnant women in Poland during the pandemic. 译：疫情期间波兰孕妇新冠疫苗接种依从性 Front Public Health（IF 3） · Hinca KM 等 · 2026 10.3389/fpubh.2026.1917171 13. Lifestyle factors or protective behaviors: which are more strongly associated with upper respiratory tract infections after COVID-19? A cross-sectional study of 1,535 Chinese college students. 译：生活方式还是保护行为：与上呼吸道感染关联更强者为何 Front Public Health（IF 3） · He C 等 · 2026 10.3389/fpubh.2026.1958833 14. COVID-19 outcomes in patients with inflammatory rheumatic diseases: associations with disease subtypes, treatments, and vaccination status. 译：炎症性风湿病患者新冠结局与疾病修饰治疗的关联 Front Public Health（IF 3） · Ak F 等 · 2026 10.3389/fpubh.2026.1907698 15. Pulmonary Herpes Simplex Virus Reactivation in Invasively Mechanically Ventilated Patients With COVID-19 in Intensive Care Unit. 译：机械通气患者肺内单纯疱疹病毒再激活 J Med Virol（IF 2.7） · Zarlenga B 等 · 2026 10.1002/jmv.71170 16. Maternal COVID-19 During Pregnancy and Offspring Neurodevelopmental Disorders: A Nationwide Birth Cohort Study. 译：孕期新冠感染与子代神经发育障碍：全国性研究 Pediatr Infect Dis J（IF 2.4） · Okubo Y 等 · 2026 10.1097/INF.0000000000005436 17. Persistent Immune Thrombocytopenia as a Post-Acute Sequelae of COVID-19: A Case Report. 译：新冠急性后期后遗症之持续性免疫性血小板减少：病例报告 Public Health Chall · Riazullah 等 · 2026 10.1002/puh2.70412 18. Investigation of the physical and emotional status of elderly individuals with and without COVID-19: a cross-sectional study. 译：有/无长新冠老年人身心状况调查 Geriatr Nurs · Mutlu A 等 · 2026 10.1016/j.gerinurse.2026.104373 19. Pediatric intracranial infections complicating bacterial sinusitis in Canada. 译：加拿大细菌性鼻窦炎并发儿童颅内感染 J Neurosurg Pediatr · Richards C 等 · 2026 10.3171/2026.5.PEDS25668 20. Regional and national burden of attention-deficit hyperactivity disorder in Asia, 1990-2023: a Global Burden of Disease Study 2023. 译：亚洲注意缺陷多动障碍区域与国家负担（1990-2021） World J Pediatr · Choi Y 等 · 2026 10.1007/s12519-026-01091-w 其余 61 篇未列出（低影响因子期刊或主题相关度较低）流感与其他呼吸道病毒（26 篇） 1. Influenza A virus infection induces immune dysregulation in the placenta and fetus without vertical transmission in nonhuman primates. 译：甲型流感病毒感染引发胎盘与胎儿免疫失调（不依赖垂直传播） Sci Adv（IF 11.7） · Cervantes O 等 · 2026 10.1126/sciadv.aee9861 2. Maternal Influenza Infection During Pregnancy and Neuropsychiatric Disorders in Offspring. 译：孕期流感感染与子代神经精神障碍：全国性队列研究 JAMA Netw Open（IF 10.5） · Kong J 等 · 2026 10.1001/jamanetworkopen.2026.37902 3. Influenza virus research in an era of emerging respiratory threats: host-virus interactions, surveillance technologies, antiviral management and resistance, and vaccine preparedness. 译：新发呼吸道威胁时代的流感研究：宿主-病毒互作 Front Microbiol（IF 4） · Hu M 等 · 2026 10.3389/fmicb.2026.1949447 4. Epidemiology and lagged climatic drivers of pediatric viral lower respiratory tract infections in Tianjin, China (2023-2025). 译：儿童病毒性下呼吸道感染的流行病学与滞后气候驱动因素 Front Cell Infect Microbiol（IF 3.9） · Mu S 等 · 2026 10.3389/fcimb.2026.1893926 5. Distinct influenza interfaces in cattle: repeated spillovers of highly pathogenic avian influenza A(H5N1) from wild birds and enzootic circulation of influenza D virus. 译：牛群中不同的流感界面：高致病性禽流感的反复溢出 Front Cell Infect Microbiol（IF 3.9） · Wang S 等 · 2026 10.3389/fcimb.2026.1957795 6. Detection of Aspergillus in the lower respiratory tract and its association with mortality in patients with different viral pneumonias: a retrospective multicenter cohort study from China. 译：下呼吸道曲霉属检出及其与死亡的关联 Front Cell Infect Microbiol（IF 3.9） · Li X 等 · 2026 10.3389/fcimb.2026.1906021 7. Mathematical modeling of in vitro replication dynamics for multiple highly pathogenic avian influenza clade 2.3.4.4 viruses in chicken and duck cells. 译：多种高致病性禽流感体外复制动力学的数学建模 Microbiol Spectr（IF 3.3） · Bordes L 等 · 2026 10.1128/spectrum.00843-26 8. Age-related heterogeneity in diagnosis-coded pediatric Mycoplasma pneumoniae-associated hospitalizations and PICU-associated care: a single-center retrospective study. 译：诊断编码儿科肺炎支原体相关事件的年龄异质性 Front Public Health（IF 3） · Chen M 等 · 2026 10.3389/fpubh.2026.1875440 9. Enrollment in participatory surveillance programs and influenza vaccination uptake: A systematic review protocol. 译：参与式监测项目参与情况与流感疫苗接种：系统综述 PLoS One（IF 2.9） · Kanma-Okafor OJ 等 · 2026 10.1371/journal.pone.0358599 10. Association between air sampling for viral respiratory pathogens and acute respiratory tract infection cases in the emergency department. 译：呼吸道病毒气溶胶采样与急性呼吸道感染的关联 Infect Control Hosp Epidemiol（IF 2.4） · Griffin M 等 · 2026 10.1017/ice.2026.10538 11. School-age Children as the Dominant Source of Inter-seasonal Influenza Circulation in the Republic of Korea, 2022-2025. 译：学龄儿童是流感流行间期传播的主要来源 Pediatr Infect Dis J（IF 2.4） · Shim YK 等 · 2026 10.1097/INF.0000000000005434 12. Comparable burden of severe acute respiratory illness among children and older adults in Kenya: evidence from a multi-site health utilization survey. 译：儿童与老年人的重症急性呼吸道感染负担相当 IJID Reg · Osoro E 等 · 2026 10.1016/j.ijregi.2026.101011 13. Influenza vaccination in childhood and adolescence. Evaluation of the 2025-2026 campaign in Spain and improvement strategies. Report by AEV, CAV-AEP and SEIP. 译：儿童与青少年流感疫苗接种：2025-26流行季效果评估 An Pediatr (Engl Ed) · Alvarez Aldeán J 等 · 2026 10.1016/j.anpede.2026.504373 14. Dairy producers' perceptions of highly pathogenic avian influenza (HPAI) H5N1 and their influence on implementation of biosecurity changes. 译：奶牛养殖者对高致病性禽流感H5N1的认知与应对 J Dairy Sci · Mohanto K 等 · 2026 10.3168/jds.2026-29246 15. Community-acquired Acinetobacter baumannii pneumonia in Southern Vietnam: A retrospective cohort study. 译：越南南部社区获得性鲍曼不动杆菌肺炎：回顾性研究 Medicine (Baltimore) · Le-Thi TH 等 · 2026 10.1097/MD.0000000000050995 16. Influenza disease burden investigation and cost-effectiveness analysis based on system dynamics model. 译：基于系统动力学的流感疾病负担调查与成本效益分析 Eur J Health Econ · Cao L 等 · 2026 10.1007/s10198-026-01987-4 17. Genetic Characterization of Highly Similar H9N2 Viruses Isolated from Swine and Poultry in China. 译：猪源与禽源高度相似H9N2病毒的遗传特征 Microb Pathog · Hong T 等 · 2026 10.1016/j.micpath.2026.108868 18. Multidrug resistance in bacteria causing community-acquired urinary tract infections among adult outpatients attending primary healthcare facilities in Mwanza, Tanzania. 译：社区获得性尿路感染病原菌的多重耐药 PLOS Glob Public Health · Emmanuel EG 等 · 2026 10.1371/journal.pgph.0005638 19. Monitoring influenza-like symptoms in the UK through participatory surveillance: Insights from FluSurvey over two winter seasons (2023-24 and 2024-25). 译：英国参与式监测流感样症状：人群洞察 PLOS Digit Health · Green RE 等 · 2026 10.1371/journal.pdig.0001714 20. Patient and caregiver burden after hospitalization with severe viral lower respiratory tract disease: results from a real-world survey in Europe, the US and Japan. 译：重症病毒性下呼吸道感染住院后的患者与照护者负担 Curr Med Res Opin · Gordon AC 等 · 2026 10.1080/03007995.2026.2741493 其余 6 篇未列出（低影响因子期刊或主题相关度较低）结核病（15 篇） 1. Lung function trajectories after pulmonary tuberculosis in children and adolescents: a prospective cohort study. 译：儿童青少年肺结核后肺功能轨迹：前瞻性队列 Thorax（IF 9.4） · Nkereuwem E 等 · 2026 10.1136/thorax-2026-225077 2. Rethinking tuberculosis and human immunodeficiency virus as a syndemic: Implications for global prevention and care. 译：重新审视结核-HIV共流行：对防控的启示 Prev Med（IF 3.3） · Mandal RK 等 · 2026 10.1016/j.ypmed.2026.108677 3. Analysis of tuberculosis prevalence surveys in Africa: evidence to change the status quo in case finding. 译：非洲结核患病率调查分析：改变现状的证据 Front Public Health（IF 3） · Mukherjee JS 等 · 2026 10.3389/fpubh.2026.1941743 4. Impact of policy shifts and festival holidays on tuberculosis surveillance: a time-series analysis in Southwest China (2014-2024). 译：政策调整与节假日对结核监测的影响：时间序列研究 Front Public Health（IF 3） · Luo Q 等 · 2026 10.3389/fpubh.2026.1900071 5. Tuberculosis disease burden trends, drivers, and projections to 2050 in China and the wider Central Asian region, 1990-2023. 译：中国及全球结核负担趋势、驱动因素与2050年预测 PLoS One（IF 2.9） · Tuohetaerbaike B 等 · 2026 10.1371/journal.pone.0358349 6. Workplace physical environmental factors associated with pulmonary tuberculosis among workers: a scoping review. 译：与工人肺结核相关的工作场所物理环境因素 IJID Reg · Sholehhudin M 等 · 2026 10.1016/j.ijregi.2026.101010 7. Heterogeneity in Mycobacterium tuberculosis immunoreactivity in young children in Blantyre, Malawi: A community-based survey. 译：马拉维布兰太瑞幼儿结核菌免疫反应性的异质性 PLOS Glob Public Health · Rickman HM 等 · 2026 10.1371/journal.pgph.0007269 8. Circulating TGF-β and SMAD3 in relation to early fibrotic lung changes and pulmonary function in pulmonary tuberculosis: A prospective cohort study. 译：循环TGF-β与SMAD3：早期肺纤维化改变与肺功能 Cytokine · Putrawan HA 等 · 2026 10.1016/j.cyto.2026.157222 9. Measurement of Tuberculosis treatment adherence: A methodological scoping review of observational studies. 译：结核治疗依从性测量：观察性研究方法学范围综述 PLOS Glob Public Health · Ramos JP 等 · 2026 10.1371/journal.pgph.0007422 10. Ambient temperature variability and newly diagnosed tuberculosis: Evidence from a time-stratified case-crossover study. 译：环境温度变异与新诊断结核：时间序列证据 Environ Epidemiol · Zhang J 等 · 2026 10.1097/EE9.0000000000000531 11. Tuberculosis Incidence and Predictors Among People Living With HIV After Isoniazid-Rifapentine (3HP) Preventive Therapy in Ethiopia: A Retrospective Cohort Study. 译：HIV感染者异烟肼-利福喷丁预防治疗后结核发病率及预测因素 J Trop Med · Etu ES 等 · 2026 10.1155/jotm/4521687 12. Implementation of next-generation sequencing to guide care and public health action in settings with high burden of rifampicin-resistant tuberculosis: 32 stakeholder consensus statements generated using Delphi principles. 译：二代测序指导临床照护与公共卫生行动的实施 BMJ Public Health · Dippenaar A 等 · 2026 10.1136/bmjph-2026-004957 13. Association of Helicobacter pylori Coinfection With Tuberculosis Disease Severity and Treatment Outcomes. 译：幽门螺杆菌共感染与结核严重程度及治疗转归 J Trop Med · Baluku JB 等 · 2026 10.1155/jotm/9151347 14. Fractal-fractional model for analysis of tuberculosis infection using Ethiopia incidence data. 译：分析埃塞俄比亚结核发病的分形分数阶模型 Quant Biol · Cheneke KR 等 · 2026 10.1002/qub2.70045 15. Nonlinear analysis of factors influencing tuberculosis outpatient visits in China: an explainable machine learning approach. 译：中国结核门诊就诊量影响因素的非线性分析 Geospat Health · Wang H 等 · 2026 10.4081/gh.2026.1535 HIV与性传播疾病（67 篇） 1. Epidemiological trends of HIV among individuals aged 15-54 years in South Africa from 2004 to 2025: a population-based, longitudinal cohort study. 译：南非15-54岁人群HIV流行趋势（2004-2025）：人群纵向队列研究 Lancet HIV（IF 14.6） · Okango E 等 · 2026 10.1016/S2352-3018(26)00180-300180-3) 2. Cutting Out Stigma: Findings From a Pilot Implementation Trial of a Barbershop-Based HIV Stigma Reduction and Health Promotion Intervention in the Southern United States. 译：理发店HIV检测试点实施试验：消除污名项目结果 J Int AIDS Soc（IF 4.8） · Perkins JM 等 · 2026 10.1002/jia2.70195 3. Fidelity of Implementation of Oral Pre-Exposure Prophylaxis for HIV in Public Family Planning Clinics in Kenya: Results From a Stepped-Wedge Cluster Randomized Trial. 译：公立计划生育门诊口服HIV暴露前预防(PrEP)的实施保真度 J Int AIDS Soc（IF 4.8） · Mukui IN 等 · 2026 10.1002/jia2.70189 4. Metabolic Dysfunction-Associated Steatohepatitis and the Progression of Cognitive Decline in Older Thai People With HIV. 译：HIV感染者代谢功能障碍相关脂肪性肝炎与认知衰退进展 J Int AIDS Soc（IF 4.8） · Porkaew K 等 · 2026 10.1002/jia2.70215 5. PrEP Use and Willingness Cascades Among Transgender Women in 11 Asian Countries: Findings From the PrEP APPEAL Cross-Sectional Online Survey. 译：11个亚洲国家跨性别女性PrEP使用与意愿级联 J Int AIDS Soc（IF 4.8） · Wolter A 等 · 2026 10.1002/jia2.70209 6. Optimizing pneumococcal prevention in South African older adults: Cost-effectiveness of PCV20 versus PPSV23 in the context of HIV-associated risk. 译：南非老年人肺炎球菌预防优化：疫苗策略成本效益分析 Hum Vaccin Immunother（IF 4.6） · Wang WW 等 · 2026 10.1080/21645515.2026.2741765 7. Immune remodeling in HPV-associated cervical disease. 译：HPV相关宫颈疾病中的免疫重塑 Front Cell Infect Microbiol（IF 3.9） · Chulenbayeva L 等 · 2026 10.3389/fcimb.2026.1918480 8. Beyond cervicovaginal limitations: potential bidirectional interactions between HPV infection and mucosal microbiota from oral, anorectal and penile sites - a mini-review. 译：超越宫颈阴道局限：HPV感染与肠道菌群潜在双向互作 Front Cell Infect Microbiol（IF 3.9） · Liu W 等 · 2026 10.3389/fcimb.2026.1962165 9. Incident and Recurrent Sexually Transmitted Infections by Gender Identity Among Sex Workers on HIV Pre-Exposure Prophylaxis: A Prospective Cohort Study. 译：不同性别认同性工作者新发与复发性传播感染 Int J Infect Dis（IF 3.6） · Valencia J 等 · 2026 10.1016/j.ijid.2026.109169 10. Age-based outcomes of antiretroviral therapy for people living with HIV in current follow-up: a comparative retrospective cohort study, Ganzhou, China, 2001-2021. 译：现行随访模式下不同年龄段HIV感染者抗病毒治疗结局 Int J Infect Dis（IF 3.6） · Lian CX 等 · 2026 10.1016/j.ijid.2026.109173 11. Higher plasma kynurenine-tryptophan ratio predicts incident hepatic fibrosis in women with HIV. 译：血浆犬尿氨酸/色氨酸比值预测HIV感染女性新发肝纤维化 AIDS（IF 3.4） · Duarte MJ 等 · 2026 10.1097/QAD.0000000000004633 12. Consent understanding and willingness to participate in research among adolescents and young adults living with HIV. 译：青少年与青年对研究参与知情同意的理解与意愿 AIDS（IF 3.4） · John-Stewart G 等 · 2026 10.1097/QAD.0000000000004638 13. Adherence to European AIDS clinical society hepatitis B management guidelines in people with HIV: real-world evidence from Spain and Germany. 译：HIV感染者对欧洲艾滋病临床学会乙肝管理指南的依从性 AIDS（IF 3.4） · Berenguer J 等 · 2026 10.1097/QAD.0000000000004635 14. Exercise testing and single-photon emission computed tomography myocardial perfusion imaging to detect silent coronary heart disease in people with HIV. 译：HIV感染者运动试验与SPECT心肌灌注成像评估 AIDS（IF 3.4） · Cresta M 等 · 2026 10.1097/QAD.0000000000004637 15. Female sex is associated with continuous decline in intact HIV-1 proviruses during long-term antiretroviral therapy. 译：女性性别与长期治疗中完整HIV-1前病毒持续下降相关 AIDS（IF 3.4） · Li Y 等 · 2026 10.1097/QAD.0000000000004632 16. High prevalence of human papillomavirus at different steps of assisted reproductive procedures. 译：辅助生殖流程各环节人乳头瘤病毒(HPV)高检出率 J Clin Virol（IF 3.3） · Mery L 等 · 2026 10.1016/j.jcv.2026.106015 17. HIV breakthrough infection after 6 years of daily TDF/FTC oral PrEP with objectively documented optimal adherence. 译：每日口服TDF/FTC型PrEP使用六年后HIV突破感染（客观服药记录） Sex Transm Infect（IF 3.1） · Bana NB 等 · 2026 10.1136/sextrans-2026-057198 18. Comparing Structural Determinants, Psychosocial Factors, and Individual-Level Risk Indicators for Women's HIV Prevention in the Urban South. 译：结构性决定因素、心理社会因素与个体风险指标的比较 J Acquir Immune Defic Syndr（IF 3） · LeCates A 等 · 2026 10.1097/QAI.0000000000003984 19. Prevalence and genotype distribution of human papillomavirus infection among women undergoing HPV testing at a hospital in Zhangzhou, China: a retrospective study. 译：未成年女性HPV感染患病率与基因型分布 Front Public Health（IF 3） · Xu W 等 · 2026 10.3389/fpubh.2026.1907680 20. Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study. 译：津巴布韦HIV感染者高血糖与血脂异常的负担和决定因素 PLoS One（IF 2.9） · Chirimo R 等 · 2026 10.1371/journal.pone.0359196 其余 47 篇未列出（低影响因子期刊或主题相关度较低）虫媒与热带病（47 篇） 1. Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study. 译：赞比亚青蒿素部分耐药的证据：分子流行病学与临床研究 Lancet Infect Dis（IF 29.4） · Mwenda M 等 · 2026 10.1016/S1473-3099(26)00478-000478-0) 2. Sickle cell haemoglobin status shapes malaria parasite genotype in asymptomatic infections. 译：镰状细胞血红蛋白状态塑造无症状感染者疟原虫基因型 Nat Microbiol（IF 20.7） · Hopson HD 等 · 2026 10.1038/s41564-026-02502-4 3. Circular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission. 译：编码Pvs25的环状RNA疫苗诱导间日疟传播阻断抗体 Vaccine（IF 4.5） · Kunkeaw N 等 · 2026 10.1016/j.vaccine.2026.129221 4. Demographic and epidemiological patterns of reported malaria cases in Aseer Region, Saudi Arabia: An eight-year surveillance analysis. 译：沙特阿西尔地区疟疾报告病例的人口学与流行病学模式 J Infect Public Health（IF 4.3） · Alraey Y 等 · 2026 10.1016/j.jiph.2026.103384 5. Modeling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria. 译：cabamiquine-咯萘啶用于恶性疟化学预防的潜在效果建模 Antimicrob Agents Chemother（IF 4.1） · Okell LC 等 · 2026 10.1128/aac.00434-26 6. Risk factors of imported malaria in Bhutan: A retrospective analysis (2013-2024). 译：不丹输入性疟疾的风险因素（2013-2024年回顾分析） Travel Med Infect Dis（IF 4） · Penjor K 等 · 2026 10.1016/j.tmaid.2026.103026 7. Thorsellia dominance and bacterial community structure in two major malaria vectors: an exploratory study in Northwestern Argentina. 译：两种主要疟疾病媒中Thorsellia菌优势与细菌群落结构 Front Microbiol（IF 4） · Duque PL 等 · 2026 10.3389/fmicb.2026.1895126 8. Retrospective two-centre study of human tularemia, Austria. 译：奥地利人间土拉菌病两中心回顾性研究 Infection（IF 3.9） · Schubert L 等 · 2026 10.1007/s15010-026-03007-2 9. Evaluating periportal fibrosis in schistosomiasis mansoni using the ELF [Enhanced Liver Fibrosis] score: A pilot study. 译：ELF评分评估曼氏血吸虫病门脉周围纤维化 PLoS Negl Trop Dis（IF 3.4） · Thorp RD 等 · 2026 10.1371/journal.pntd.0014775 10. Impact of praziquantel treatment and early reinfection patterns in a mixed Schistosoma mansoni and Schistosoma haematobium infection focus in the Democratic Republic of Congo. 译：混合血吸虫感染的吡喹酮治疗效果与早期再感染模式 PLoS Negl Trop Dis（IF 3.4） · Madinga JN 等 · 2026 10.1371/journal.pntd.0014764 11. Impact of temperature on patient-derived dengue virus breakthrough infections in wMel-infected Aedes aegypti. 译：温度对wMel沃尔巴克氏体蚊株登革突破感染的影响 PLoS Negl Trop Dis（IF 3.4） · da Silva Gonçalves D 等 · 2026 10.1371/journal.pntd.0014255 12. Development and effectiveness test of an internet-based real-time monitoring device for malaria parasite vector mosquitoes. 译：基于互联网的病媒实时监测装置研发与效果测试 PLoS Negl Trop Dis（IF 3.4） · Han C 等 · 2026 10.1371/journal.pntd.0014778 13. Serological evidence of subclinical Usutu virus exposure among West Nile virus-seropositive individuals in Israel. 译：西尼罗病毒血清阳性者中乌苏图病毒亚临床暴露的血清学证据 J Clin Virol（IF 3.3） · Tomer E 等 · 2026 10.1016/j.jcv.2026.106014 14. Household representatives' understanding of dengue solutions and larval indices surveillance systems in southern Thailand: A mixed methods study. 译：户主对登革防控措施的认知与幼虫指数监测 PLoS One（IF 2.9） · Suwanbamrung C 等 · 2026 10.1371/journal.pone.0348142 15. High prevalence of Plasmodium ovalewallikeri in co-infections with Plasmodium falciparum in symptomatic than asymptomatic Plasmodium parasite infections in Kisumu, Kenya. 译：与恶性疟原虫共感染中卵形疟原虫wallikeri亚种高患病率 PLoS One（IF 2.9） · Juma JA 等 · 2026 10.1371/journal.pone.0334188 16. Spatial and genetic dynamics of Plasmodium falciparum histidine-rich protein2 in sub-Saharan Africa. 译：撒哈拉以南恶性疟原虫组氨酸富集蛋白2基因缺失的空间与遗传动态 PLoS One（IF 2.9） · Lambe KO 等 · 2026 10.1371/journal.pone.0358132 17. Vector competence for dengue-2 virus of permethrin resistant/ susceptible Aedes aegypti sub-populations from selected sites in Lamu County, Kenya. 译：溴氰菊酯抗性与敏感埃及伊蚊对登革2型病毒的媒介能力 PLoS One（IF 2.9） · Qureish KS 等 · 2026 10.1371/journal.pone.0359810 18. Rethinking Clinical Trial Design to Accelerate Therapeutics for Arboviral Epidemics. 译：重新设计临床试验以加速虫媒病毒疫情治疗药物研发 Open Forum Infect Dis（IF 2.8） · Alemany A 等 · 2026 10.1093/ofid/ofag565 19. Altitudinal cross-sectional study of the sand fly fauna of the highlands of Tigray Region, northern Ethiopia. 译：提格雷高地白蛉区系的海拔梯度横断面调查 Acta Trop（IF 2.1） · Gebremariam A 等 · 2026 10.1016/j.actatropica.2026.108339 20. Plasmodium protein kinase 2 is required for ookinete-to-oocyst transition and parasite transmission. 译：疟原虫蛋白激酶2是动合子-卵囊转变与寄生虫传播所必需 Life Sci Alliance · Pashley SL 等 · 2026 10.26508/lsa.202603863 其余 27 篇未列出（低影响因子期刊或主题相关度较低）病毒性肝炎（19 篇） 1. Low-level of mitochondrial DNA alterations during direct-acting antiviral treatment in leukocytes of people who inject drugs living with HCV. 译：丙肝直接抗病毒治疗期间线粒体DNA的低水平改变 Microbiol Spectr（IF 3.3） · Gay L 等 · 2026 10.1128/spectrum.01946-26 2. Seroprevalence and trends of transfusion-transmissible infections among blood donors in the Volta Region, Ghana: A four-year retrospective study. 译：献血人群输血传播感染的血清阳性率与趋势 PLoS One（IF 2.9） · Ayanku S 等 · 2026 10.1371/journal.pone.0349548 3. Efficacy of direct-acting antiviral regimens for acute HCV infection: a systematic review and meta-analysis. 译：急性丙肝直接抗病毒方案疗效：系统综述与荟萃分析 Virol J（IF 2.5） · Mansour N 等 · 2026 10.1186/s12985-026-03307-x 4. Impact of metabolic dysfunction-associated steatotic liver disease on the development of hepatocellular carcinoma after HCV cure. 译：代谢功能障碍相关脂肪肝对后续疾病发生的影响 Ann Hepatol · Ogawa E 等 · 2026 10.1016/j.aohep.2026.102455 5. Cost-effectiveness of opportunistic age-based hepatitis C screening using pooled HCV RNA testing in Galicia, Spain. 译：基于HCV RNA混样检测的年龄机会性丙肝筛查成本效益 Rev Esp Enferm Dig · Aguilera A 等 · 2026 10.17235/reed.2026.12096/2026 6. The Clinical Utility of Adding Laminin Gamma 2 Monomer to the PAGE-B Score for Hepatocellular Carcinoma Surveillance in Chronic Hepatitis B. 译：层粘连蛋白γ2单体联合PAGE-B评分对肝细胞癌的临床效用 J Gastroenterol Hepatol · Huang CF 等 · 2026 10.1111/jgh.70792 7. Chronic Hepatitis B Prevalence and Care Among Medicaid Beneficiaries. 译：医保受益人群慢性乙肝患病率与照护现状 Med Care · Pham H 等 · 2026 10.1097/MLR.0000000000002387 8. Detection of Acute Hepatitis C Outbreaks in California Using SaTScan: Statewide Spatiotemporal Analysis. 译：加州利用SaTScan时空扫描检测急性丙肝暴发 JMIR Public Health Surveill · New S 等 · 2026 10.2196/104761 9. Trends in hepatitis B virus seroprevalence in a large cohort of adult cancer patients from 2010 to 2023. 译：大型癌症患者队列乙肝血清阳性率趋势 Cancer Causes Control · Rossi de Camargo Pinto M 等 · 2026 10.1007/s10552-026-02262-w 10. Seroprevalence and Clinical Characteristics of Hepatitis D Virus Infection in Korean Patients with Chronic Hepatitis B, Liver Cirrhosis, and Hepatocellular Carcinoma. 译：韩国丁型肝炎病毒感染的血清阳性率与临床特征 Gut Liver · Park MK 等 · 2026 10.5009/gnl260141 11. Early Antiviral Therapy and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: A Prospective Phase II Study. 译：慢性乙肝早期抗病毒治疗与肝细胞癌发病率 Gut Liver · Sinn DH 等 · 2026 10.5009/gnl260219 12. Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy. 译：慢性乙肝患者胰岛素抵抗与肝细胞癌发生 J Korean Med Sci · Sinn DH 等 · 2026 10.3346/jkms.2026.41.e248 13. Regional distribution of serological evidence of vaccine-induced immunity to hepatitis B among cancer patients in a city in southeastern Brazil. 译：乙肝疫苗诱导免疫血清学证据的区域分布 Rev Inst Med Trop Sao Paulo · Paula VG 等 · 2026 10.1590/S1678-9946202668066 14. Association of Hepatitis B Virus Ribonucleic Acid with Type 2 Diabetes Mellitus in Chronic Hepatitis B. 译：慢性乙肝患者HBV RNA与2型糖尿病的关联 J Coll Physicians Surg Pak · Chen X 等 · 2026 10.29271/jcpsp.2026.10.1260 15. Diagnostic Performance of the Neutrophil-to-Lymphocyte Ratio for the Identification of Insulin Resistance in Patients with Fibrotic Chronic Hepatitis C: a Case-Control Study. 译：中性粒细胞-淋巴细胞比值鉴别感染的诊断性能 Cell Physiol Biochem · Alnaqqash YR 等 · 2026 10.33594/000000892 16. Association of nucleos(t)ide analogue treatment history with mortality in HBV-DNA-positive HBV-ACLF: a multicenter cohort study. 译：核苷(酸)类似物治疗史与HBV-DNA阳性患者死亡率 Front Immunol · Shen L 等 · 2026 10.3389/fimmu.2026.1942114 17. Seroprevalence and Potential Correlation of Transfusion-Transmitted Infections With the ABO Blood Group System Among Blood Donors in Eastern India. 译：输血传播感染血清阳性率及其潜在关联 Cureus · Nayan N 等 · 2026 10.7759/cureus.115870 18. Phylodynamic analysis provides insights into genotype displacement of duck hepatitis A virus in China. 译：系统动力学分析揭示鸭甲肝病毒基因型更替 J Vet Sci · Xie C 等 · 2026 10.4142/jvs.25210 19. Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial. 译：索磷布韦/达拉他韦对比格卡瑞韦/艾尔巴韦治疗慢性丙肝 Acta Med Indones · Sulaiman AS 等 · 2026 疫苗与免疫策略（29 篇） 1. Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study. 译：孕前四价HPV疫苗接种与妊娠结局：瑞典全国人群病例对照研究 BMJ（IF 42.7） · Zhang Z 等 · 2026 10.1136/bmj-2026-100739 2. Expression of concern-Effect of Brazil's national human papillomavirus vaccination programme on the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 in women aged 20-24 years: a population-based study. 译：编辑关注声明——巴西国家HPV疫苗接种计划效果研究 Lancet Glob Health（IF 28.9） · The Editors Of The Lancet Global Health 等 · 2026 10.1016/j.langlo.2026.104113 3. Global, regional, and national burden of tetanus in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. 译：204个国家和地区破伤风负担（1990-2023）：GBD 2023系统分析 EClinicalMedicine（IF 9.6） · GBD 2023 Tetanus Collaborators 等 · 2026 10.1016/j.eclinm.2026.104202 4. Interventions to mitigate post-infection morbidity: Management insights from simple models. 译：减轻感染后发病率：来自简单模型的管理启示 Proc Natl Acad Sci U S A（IF 9.4） · Jaiswal P 等 · 2026 10.1073/pnas.2609982123 5. Novel EG95-based mRNA vaccines induce long-term protective immunity against echinococcosis. 译：基于EG95抗原的新型mRNA疫苗诱导棘球蚴病长期保护性免疫 PLoS Pathog（IF 5.5） · Chen WG 等 · 2026 10.1371/journal.ppat.1014659 6. Why does rotavirus vaccine effectiveness vary around the globe? 译：为何轮状病毒疫苗效果在全球存在差异 PLoS Pathog（IF 5.5） · Woodyear S 等 · 2026 10.1371/journal.ppat.1014670 7. Balancing individual risks and collective benefits: Effects of vaccine price, message framing, and value orientations on influenza vaccination in China. 译：平衡个体风险与群体收益：疫苗价格、信息框架与公平 Hum Vaccin Immunother（IF 4.6） · Chu Y 等 · 2026 10.1080/21645515.2026.2743369 8. Cognitive and behavioral determinants of HPV vaccination willingness and Behavior among female university students in Karnataka, India. 译：HPV疫苗接种意愿与行为的认知和行为决定因素 Hum Vaccin Immunother（IF 4.6） · Thomas Gil M 等 · 2026 10.1080/21645515.2026.2738253 9. Bridging the intention‒behavior gap in herpes zoster vaccination: A nationwide survey in a self-payment setting. 译：弥合带状疱疹疫苗接种的意愿-行为差距：韩国全国调查 Hum Vaccin Immunother（IF 4.6） · Liou FY 等 · 2026 10.1080/21645515.2026.2741764 10. Longitudinal SARS-CoV-2 mRNA vaccine immunogenicity in inflammatory bowel disease in relation to anti-TNF therapy and age: a prospective cohort study. 译：炎症性肠病患者新冠mRNA疫苗免疫原性纵向研究：治疗与年龄影响 Vaccine（IF 4.5） · Mayr W 等 · 2026 10.1016/j.vaccine.2026.129224 11. Influenza vaccine effectiveness against hospitalization in children aged 6-72 months: a test-negative study in the Southern Italy, 2022-2026. 译：流感疫苗对6-72月龄儿童住院的保护效果 Infection（IF 3.9） · Fortunato F 等 · 2026 10.1007/s15010-026-02995-5 12. Acceptability of a Prospective Chlamydia Vaccine in Sexually Active Young Adults: A Descriptive Survey. 译：性活跃青年对衣原体疫苗的可接受度：描述性研究 Sex Transm Dis（IF 2.5） · Griner SB 等 · 2026 10.1097/OLQ.0000000000002421 13. Assessing the Willingness of Future Health Care Providers to Participate in Vaccine Trials: Cross-Sectional VACCELERATE European Study. 译：未来医务工作者参与疫苗试验意愿评估 JMIR Public Health Surveill · Yiallouris A 等 · 2026 10.2196/84952 14. A multivalent mRNA-lipid nanoparticle vaccine containing eight hemagglutinin antigens elicited broad neutralizing antibody responses and protected against influenza A virus challenge in swine. 译：含八种血凝素抗原的多价mRNA-脂质纳米颗粒疫苗 J Virol · Ciacci Zanella G 等 · 2026 10.1128/jvi.00848-26 15. Influenza vaccine protection and contact patterns among outpatients with influenza-like illness during the 2024-2025 season in China: a test-negative case-control study. 译：流感样病例门诊患者的疫苗保护与接触模式 J Glob Health · Chen L 等 · 2026 10.7189/jogh.16.04253 16. Vaccination perspectives among nurses in a rural, frontier state. 译：美国农村边远州护士的疫苗接种观点 Nurs Outlook · Larson M 等 · 2026 10.1016/j.outlook.2026.102894 17. Household and Community Clustering of Concurrent Vaccine Hesitancy in China: Multicenter Survey. 译：中国疫苗犹豫的家庭与社区聚集性：多中心调查 JMIR Public Health Surveill · Zhang Y 等 · 2026 10.2196/104263 18. Review of Salmonid Alphavirus: Focus on Viral Survival, Shedding, Detection and Effects of Vaccination. 译：鲑鱼甲病毒综述：病毒存活、排毒、检测与影响 J Fish Dis · Rodger H 等 · 2026 10.1111/jfd.70301 19. From eradicating wild poliovirus to eradicating vaccine-derived polioviruses: why oral polio vaccine use must now be ended. 译：从消灭脊灰野病毒到消灭疫苗衍生脊灰病毒：口服脊灰疫苗的困境 Int Health · Durrheim DN 等 · 2026 10.1093/inthealth/ihag097 20. Rapid Motility Arrest of the Lyme Disease Spirochete, Borrelia burgdorferi, by Vaccine-Induced OspA Antibodies. 译：疫苗诱导抗体快速阻滞莱姆病螺旋体运动 Mol Microbiol · Bhattacharyya A 等 · 2026 10.1111/mmi.70122 其余 9 篇未列出（低影响因子期刊或主题相关度较低）耐药与医院感染（38 篇） 1. Metagenomic insights into the global occurrence of ESKAPE-targeting bacteriophages in urban wastewater. 译：城市污水中靶向ESKAPE细菌噬菌体的全球宏基因组分布 Water Res（IF 11.4） · Molendijk MM 等 · 2026 10.1016/j.watres.2026.127032 2. Integrating Infectious Disease Experts into Primary Care Antibiotic Stewardship: A Multicentre, Cluster-Randomised, Outcome-Assessor-Blinded Trial. 译：感染病专家融入初级保健抗菌药物管理：多方参与研究 Clin Microbiol Infect（IF 7.2） · Ronda M 等 · 2026 10.1016/j.cmi.2026.09.034 3. Comprehensive genomic characterization of multidrug-resistant Klebsiella pneumoniae from North India. 译：多重耐药肺炎克雷伯菌的全基因组特征 Front Microbiol（IF 4） · Bali NK 等 · 2026 10.3389/fmicb.2026.1831365 4. Antimicrobial resistance in uropathogens in Nigeria: pathogen profiles, resistance burden, surveillance and stewardship considerations. 译：尼日利亚尿路感染病原谱、耐药负担与风险因素 Front Microbiol（IF 4） · Alshamaa N 等 · 2026 10.3389/fmicb.2026.1934847 5. Outbreak investigation of extensively drug-resistant Acinetobacter baumannii of ST2 in the intensive care unit of a Lebanese hospital. 译：重症监护室内广泛耐药鲍曼不动杆菌ST2暴发调查 Front Cell Infect Microbiol（IF 3.9） · Sourenian T 等 · 2026 10.3389/fcimb.2026.1936280 6. Antimicrobial susceptibility patterns in Jalisco, Mexico: a snapshot of regional resistance (2021-2023). 译：墨西哥哈利斯科州抗菌药物敏感性模式：区域耐药概况 Front Cell Infect Microbiol（IF 3.9） · Méndez-Sotelo BJ 等 · 2026 10.3389/fcimb.2026.1866897 7. Direct Lateral Flow Detection of Carbapenemase-producing Acinetobacter baumannii From Screening Samples Using the RESIST ACINETO Lateral Flow Assay: A Proof-of-Concept Study. 译：侧流层析法直接检测筛查标本中产碳青霉烯酶鲍曼不动杆菌 J Hosp Infect（IF 3.7） · Kocer K 等 · 2026 10.1016/j.jhin.2026.09.028 8. Public awareness and knowledge of antibiotic use and antimicrobial resistance in Malta. 译：马耳他公众抗生素使用与耐药的认知调查 BMC Public Health（IF 3.5） · Schranz G 等 · 2026 10.1186/s12889-026-29529-w 9. Detection characteristics and antimicrobial resistance profiles of Salmonella spp. isolated from fecal cultures of inpatients at a maternal and child healthcare hospital in Shenzhen: a 5-year retrospective study. 译：沙门菌分离株检出特征与耐药谱 Microbiol Spectr（IF 3.3） · Ding T 等 · 2026 10.1128/spectrum.01536-26 10. Environmental pollutants as modifiers of antimicrobial resistance risk across food systems: a One Health perspective. 译：环境污染物作为食物系统耐药风险的修饰因素 Front Public Health（IF 3） · Dunga KE 等 · 2026 10.3389/fpubh.2026.1918334 11. Characterisation of multidrug-resistant, avian pathogenic-like Escherichia coli O78 from dairy-bred calves with atypical colisepticaemia. 译：多重耐药禽致病型大肠杆菌O78的特征分析 PLoS One（IF 2.9） · Pollock J 等 · 2026 10.1371/journal.pone.0359646 12. Hospital wastewater-based antimicrobial resistance epidemiology: a scoping review. 译：基于医院废水的耐药监测流行病学研究：范围综述 Infect Control Hosp Epidemiol（IF 2.4） · Viana-Cardenas E 等 · 2026 10.1017/ice.2026.10558 13. Nationwide Cross-Sectional Study of the Prevalence and MIC-Based Antimicrobial Resistance of Salmonella spp. in Poultry in Morocco. 译：全国横断面调查：患病率与MIC法抗菌药物耐药 Foodborne Pathog Dis（IF 2.4） · Esserghini H 等 · 2026 10.1177/15353141261494907 14. The burden of antimicrobial resistance in Iraq: an analysis from 2021. 译：伊拉克抗微生物药物耐药负担（2021年分析） IJID Reg · Tabche C 等 · 2026 10.1016/j.ijregi.2026.100976 15. Investigation of suspected Candidozyma auris outbreaks in Malaysia using integrated genomic, clinical and antifungal susceptibility analyses (Investigation of Candidozyma auris outbreaks in Malaysia). 译：马来西亚耳念假丝酵母疑似暴发的整合基因组学调查 Med Mycol · Tan XT 等 · 2026 10.1093/mmy/myag109 16. Residential proximity to intensive animal agriculture associates with increased prevalence of antimicrobial resistance in homes. 译：居住邻近集约化畜牧场与耐药菌定植率升高相关 J Expo Sci Environ Epidemiol · Dalton KR 等 · 2026 10.1038/s41370-026-00982-4 17. Antimicrobial Susceptibility Patterns and Proportion of Multidrug-Resistant Uropathogens in a Remote Tertiary Hospital in Bhutan: A Cross-Sectional Study. 译：尿路病原抗菌谱与多重耐药比例 Health Sci Rep · Tenzin S 等 · 2026 10.1002/hsr2.73364 18. Factors Associated With the Antimicrobial Resistance Profile of Uropathogenic Escherichia coli in a Referral Hospital in Northern Peru. 译：尿路致病性大肠杆菌耐药谱的相关因素 Interdiscip Perspect Infect Dis · Rodriguez-Saldaña CA 等 · 2026 10.1155/ipid/4524106 19. Source tracking and transmission of antibiotic resistance genes mediated by core microbiota in black soldier fly larvae bioconversion of doxycycline-contaminated hen manure. 译：核心微生物组介导的抗生素耐药基因溯源与传播 Insect Sci · Chen J 等 · 2026 10.1111/1744-7917.70366 20. Spatiotemporal patterns of antimicrobial resistance in shared human-animal waterpoints in the Maasai Mara Ecosystem, Kenya. 译：人畜共享水源地抗微生物耐药的时空模式 PLOS Glob Public Health · Waswala-Olewe BM 等 · 2026 10.1371/journal.pgph.0007393 其余 18 篇未列出（低影响因子期刊或主题相关度较低）新发与再现传染病（23 篇） 1. Informing an mpox stockpile investment case: epidemiological modelling and cost-benefit analysis. 译：mpox疫苗储备投资决策：流行病学建模与成本效益分析 Lancet Glob Health（IF 28.9） · Mitcham D 等 · 2026 10.1016/j.langlo.2026.104069 2. Filovirus reactive antibodies in wildlife hunting communities suggest ongoing zoonotic spillover in forested Guinea. 译：野生动物狩猎社区丝状病毒抗体提示人兽共患暴露持续存在 Nat Commun（IF 14.7） · Hood G 等 · 2026 10.1038/s41467-026-77653-3 3. Contagion-preserving compression for multiscale epidemic modeling. 译：多尺度疫情建模中保留传染性结构的压缩方法 Sci Adv（IF 11.7） · Xue L 等 · 2026 10.1126/sciadv.adz4710 4. Buffaloed in Brandenburg: Germany's first brush with foot-and-mouth disease after four decades of freedom. 译：勃兰登堡的水牛危机：德国四十余年来首次口蹄疫 Sci Adv（IF 11.7） · Eschbaumer M 等 · 2026 10.1126/sciadv.aeh6459 5. A multi-country outbreak of Salmonella Blockley associated with tomato consumption, July to October 2024. 译：与番茄消费相关的沙门菌Blockley型多国暴发（2024年7-10月） Euro Surveill（IF 9.9） · Hoban A 等 · 2026 10.2807/1560-7917.ES.2026.31.40.2500862 6. Unraveling the Transmission Dynamics and Evolutionary Trajectory of Mpox in South Korea: 2022-2025 Outbreak. 译：韩国mpox传播动力学与进化轨迹解析 Emerg Microbes Infect（IF 6.1） · Lee M 等 · 2026 10.1080/22221751.2026.2746255 7. A multi-matrix workflow for isolation, characterization, and biobanking of antimicrobial- resistant bacteria from One Health surveillance samples. 译：耐药菌分离、鉴定与生物样本库化的多基质工作流程 Front Microbiol（IF 4） · Bahr A 等 · 2026 10.3389/fmicb.2026.1855350 8. From molecular evolution to the school health room: the role of community-based public health nurses (helsesykepleiere) in one health communication on cross-species influenza transmission in Norway. 译：从分子进化到学校卫生室：社区公共卫生在热带病防治中的角色 Front Cell Infect Microbiol（IF 3.9） · Klein J 等 · 2026 10.3389/fcimb.2026.1965045 9. Sixteen Days Undetected: Growth Dynamics and the Case for Pre-Positioned Response Capacity in the 2026 Bundibugyo Virus Disease Outbreak, Democratic Republic of the Congo. 译：16天未被检出：增长动力学与前置响应能力建设 Int J Infect Dis（IF 3.6） · Verheyden JGL 等 · 2026 10.1016/j.ijid.2026.109170 10. Paediatric mpox during Sierra Leone's 2024 to 2025 clade IIb outbreak: A national surveillance and outbreak-investigation study of 415 children. 译：塞拉利昂2024-25年分支IIb暴发中的儿童mpox：全国监测 PLoS Negl Trop Dis（IF 3.4） · Ikoona EN 等 · 2026 10.1371/journal.pntd.0014785 11. Efficacy of Tecovirimat for the Treatment of Mpox Virus Infection in Humans: Systematic Review and Meta-Analysis of Randomized Controlled Trials. 译：替考韦仑治疗人间mpox感染的疗效：系统评价与荟萃分析 Rev Med Virol · Grecco DM 等 · 2026 10.1002/rmv.70215 12. Maternal and neonatal outcomes for pre-existing diabetes before and during the pandemic: A population-based study in Ontario, Canada. 译：大流行前后孕前糖尿病的母婴结局比较 J Obstet Gynaecol Can · Benham JL 等 · 2026 10.1016/j.jogc.2026.103546 13. Factors associated with measles infection during the 2025-6 outbreak in Burao, Somaliland: a case-control study. 译：索马里兰Burao 2025-26年麻疹暴发期间感染相关因素 Int Health · Yosef DK 等 · 2026 10.1093/inthealth/ihag102 14. Zoonotic arboviruses and associated risk factors in donkeys from northeastern Algeria. 译：阿尔及利亚东北部驴群人兽共患虫媒病毒及相关风险因素 Trop Anim Health Prod · Debbous M 等 · 2026 10.1007/s11250-026-05399-7 15. A double-antibody sandwich ELISA based on nanobody against the viral spike protein detects porcine epidemic diarrhea virus. 译：基于抗刺突蛋白纳米抗体的双抗体夹心ELISA检测方法 J Virol Methods · Wang D 等 · 2026 10.1016/j.jviromet.2026.115480 16. Serological and transcriptomic response of African fruit bats to immune challenge with recombinant vaccines expressing Ebola or Nipah virus antigens. 译：非洲果蝠对免疫刺激的血清学与转录组应答 R Soc Open Sci · Jax E 等 · 2026 10.1098/rsos.252189 17. National prioritisation of zoonotic diseases in Rwanda: a One Health modified Delphi consensus study. 译：卢旺达人兽共患病国家优先排序：同一健康修订德尔菲共识 BMJ Public Health · Gashegu M 等 · 2026 10.1136/bmjph-2025-004446 18. Measles outbreak in a unique sociocultural context: epidemiological investigation and control measures in Northern Brazil, 2025. 译：独特社会文化背景下的麻疹暴发：流行病学调查与防控 Rev Inst Med Trop Sao Paulo · Rosa RP 等 · 2026 10.1590/S1678-9946202668065 19. Incidence and Factors of Bacterial Zoonotic Infection in Solid Organ Transplant Recipients. 译：实体器官移植受者细菌性人兽共患感染的发病率与因素 Clin Transplant · Chiu CY 等 · 2026 10.1111/ctr.70708 20. Interplay between Evolutionary and Epidemic Timescales Challenges the Outcome of Control Policies. 译：进化与流行时间尺度的交织对控制措施效果的挑战 Phys Rev Lett · Lamata-Otín S 等 · 2026 10.1103/56yd-sfks 其余 3 篇未列出（低影响因子期刊或主题相关度较低）肠道与食源性疾病（14 篇） 1. The future of cholera genomics through the lens of clinical, public health, and research practitioners in Africa. 译：霍乱基因组学的未来：临床、公共卫生与研究视角 Lancet Microbe（IF 19） · Mokaya J 等 · 2026 10.1016/j.lanmic.2026.101528 2. Outbreak of Salmonella Agona linked to cross-contamination via doner kebab and electric knives in Hesse and Baden-Wuerttemberg, Germany, January 2022 - December 2024. 译：烤肉串交叉污染引发的沙门菌Agona血清型暴发 Int J Infect Dis（IF 3.6） · Saeed S 等 · 2026 10.1016/j.ijid.2026.109172 3. Serotype and Commodity Contributions to Quinolone Resistance Trends Among FSIS NARMS Salmonella Isolates, 2013-2023. 译：NARMS监测沙门菌喹诺酮耐药趋势：血清型与食品来源贡献 Foodborne Pathog Dis（IF 2.4） · Morales C 等 · 2026 10.1177/15353141261497353 4. Bayesian estimation of true herd-level prevalence and spatial distribution of Salmonella Dublin-seropositive dairy herds in Alberta, Canada. 译：沙门菌牛群真实患病率与空间分布的贝叶斯估计 J Dairy Sci · Shaukat W 等 · 2026 10.3168/jds.2026-29221 5. Identification of a putative novel rotavirus A VP4 genotype in bats from an urban Atlantic Forest, in the metropolitan region of Rio de Janeiro State, Southeastern Brazil. 译：城市大西洋森林蝙蝠中发现轮状病毒A疑似新VP4基因型 Arch Virol · Dias BV 等 · 2026 10.1007/s00705-026-06727-w 6. Molecular epidemiology, seroprevalence and genetic characterization of bovine rotavirus in Qinghai yaks: first identification of G6P[5] genotype. 译：牛轮状病毒分子流行病学、血清阳性率与遗传特征 Arch Virol · Huang Y 等 · 2026 10.1007/s00705-026-06758-3 7. Carcass Hygiene Outcomes Associated with Hazard Analysis and Critical Control Point (HACCP) Implementation and Stage-Specific Verification in Pig Abattoirs in Taiwan, 2018-2025. 译：HACCP体系与胴体卫生结局的关联 J Food Prot · Chou HY 等 · 2026 10.1016/j.jfp.2026.100936 8. Occurrence, load and transport-associated risk factors of Salmonella spp. in chickens sold in informal live bird markets in Centre-Nord Region, Burkina Faso. 译：上市活鸡沙门菌带菌、负荷与运输相关风险因素 Poult Sci · Tiendrébéogo WPB 等 · 2026 10.1016/j.psj.2026.107886 9. Prevalence and antimicrobial resistance profiles of Campylobacter coli, Campylobacter jejuni, and Escherichia coli in the poultry distribution network. 译：空肠弯曲菌与结肠弯曲菌的患病率和耐药谱 Front Antibiot · Dantroliya S 等 · 2026 10.3389/frabi.2026.1875259 10. E. coli O157:H7 evades CD8+ T cell immunity through T3SS-dependent suppression and limited MHCI presentation of translocated proteins. 译：大肠杆菌O157:H7经T3SS抑制CD8+T细胞免疫实现免疫逃逸 Discov Immunol · Hassan A 等 · 2026 10.1093/discim/kyag017 11. Phylogenetic network reconstruction reveals reassortment signatures at segment and genotype levels in human Rotavirus A. 译：系统发育网络重建揭示节段与基因型水平的重配特征 bioRxiv · Gunasekera S 等 · 2026 10.64898/2026.08.11.744215 12. Knowledge and preventive practices associated with anticipatory action for climate-related cholera outbreaks in Mozambique: a gender perspective. 译：气候相关预警行动的知识与预防实践 Res Sq · Taimo T 等 · 2026 10.21203/rs.3.rs-10341621/v1 13. Azithromycin minimum inhibitory concentration (MIC) creep and clinical-microbiological profile of typhoidal and nontyphoidal Salmonella isolates from blood specimens at a tertiary care hospital in Pune, India. 译：阿奇霉素最低抑菌浓度漂移及临床微生物学表现 Indian J Med Res · Chavan SS 等 · 2026 10.25259/IJMR_1311_2025 14. Characterization of thermophilic Campylobacter species from diarrhoeic dogs referred to veterinary hospitals in Ilorin, Kwara State, Nigeria. 译：腹泻犬来源嗜热弯曲菌的特征分析 Iran J Vet Res · Ahmed AO 等 · 2026 10.22099/ijvr.2026.51251.7601 监测预警与数学模型（21 篇） 1. Plasmid-Host Networks Reveal Persistent Mobile Elements Across Wastewater Treatment. 译：质粒-宿主网络揭示污水处理厂中的持久性可移动元件 Nat Commun（IF 14.7） · Zhou S 等 · 2026 10.1038/s41467-026-77447-7 2. A process-resolved risk prioritization framework reveals hidden antibiotic control deficiencies in wastewater treatment trains. 译：过程分辨的风险优先级框架揭示抗生素管控隐性缺口 Water Res（IF 11.4） · Lu X 等 · 2026 10.1016/j.watres.2026.127080 3. Potential health impacts and costs of active case finding guided by Mycobacterium tuberculosis immunoreactivity survey results in Blantyre, Malawi: A mathematical modeling study. 译：结核菌免疫反应性调查引导主动病例发现的健康影响与成本：马拉维建模研究 PLoS Med（IF 11） · Kim S 等 · 2026 10.1371/journal.pmed.1005272 4. A three-generation mpox cluster in Chongqing, 2024: transmission chain investigation and phylogenetic characterization. 译：重庆2024年一起三代人mpox聚集疫情：传播链调查 Infection（IF 3.9） · Li T 等 · 2026 10.1007/s15010-026-02985-7 5. Global spread and evolutionary trajectories of HIV-1 CRF01_AE: Insights from phylogenetic analysis. 译：HIV-1 CRF01_AE重组型全球传播与进化轨迹 PLoS One（IF 2.9） · Li X 等 · 2026 10.1371/journal.pone.0360404 6. Facilitators and barriers to community-based livestock abortion reporting for Rift Valley Fever surveillance in Uganda: A COM-B analysis. 译：社区牲畜流产报告促进裂谷热监测的促进与阻碍因素 PLoS One（IF 2.9） · Walekhwa AW 等 · 2026 10.1371/journal.pone.0359872 7. Genetic Diversity and Biological Characteristics of a Novel Feline Calicivirus Strain Isolated From Zoo-Captive South China Tiger (Panthera tigris amoyensis). 译：一株新型猫杯状病毒的遗传多样性与生物学特性 Transbound Emerg Dis（IF 2.9） · Ding Y 等 · 2026 10.1155/tbed/4900253 8. Integrating mathematical modelling and artificial intelligence to combat emerging viral syndemics: A systematic review. 译：整合数学建模与人工智能对抗新发病毒病 New Microbes New Infect · Cabrera-Rodríguez R 等 · 2026 10.1016/j.nmni.2026.101843 9. Multilingual Disparities in Large Language Model-Based Symptom Detection for Global Disease Surveillance: Evaluation Study. 译：大语言模型症状检测的多语种差异对全球疾病监测的影响 JMIR AI · Jannah SZ 等 · 2026 10.2196/103321 10. Meta-analytical federated surveillance for incubation period with interval- and right-censored data with stochastic variational inference. 译：区间与右删失数据下潜伏期的元分析联邦监测 Biometrics · Yoneoka D 等 · 2026 10.1093/biomtc/ujag172 11. Pathology-specific carcass weight penalties and economic losses in slaughtered pigs from Cameroon's Western Highlands: an abattoir surveillance study. 译：屠宰猪病理特异性胴体降级与经济损失 Trop Anim Health Prod · Fabrice ND 等 · 2026 10.1007/s11250-026-05379-x 12. Monitoring disease trends and characterization of non-typhoidal Salmonella isolates from community wastewater in a mid-sized city in Florida, USA: a retrospective study. 译：非伤寒沙门菌分离株的疾病趋势监测与特征分析 Appl Environ Microbiol · Rainey AL 等 · 2026 10.1128/aem.01540-26 13. Predicting myxomatosis distribution in Iberian hares (Lepus granatensis) through active surveillance. 译：通过主动监测预测粘液瘤病在伊比利亚野兔中的分布 Prev Vet Med · Cardoso B 等 · 2026 10.1016/j.prevetmed.2026.107044 14. Seroprevalence and the determinants of lumpy skin disease virus (LSDV) in cattle reared under smallholder production systems in northwestern Bangladesh. 译：圈养牛结节性皮肤病病毒的血清阳性率及决定因素 Prev Vet Med · Akther M 等 · 2026 10.1016/j.prevetmed.2026.107045 15. Public health challenges in the Americas: health surveillance, disease prevention, and equitable access to health care. 译：美洲公共卫生挑战：监测、疾病预防与环境 Cien Saude Colet · Silva Júnior JBD 等 · 2026 10.1590/1413-81232026319.16582025 16. [Haff Disease and health surveillance performance: a documental study]. 译：哈夫病与卫生监测表现：文献研究 Cien Saude Colet · Serfaty DDSM 等 · 2026 10.1590/1413-81232026319.14812024 17. Anti-Rubella antibodies seroprevalence among pregnant women in South-Western Romania. 译：罗马尼亚西南部孕妇风疹抗体血清阳性率 Front Med (Lausanne) · Radoi-Troaca LC 等 · 2026 10.3389/fmed.2026.1906798 18. Minimal residual disease in cervical cancer: biological persistence, ctHPV DNA-guided surveillance, and recurrence-directed intervention. 译：宫颈癌微小残留病：ctHPV DNA引导的监测策略 Front Oncol · Wu J 等 · 2026 10.3389/fonc.2026.1938965 19. Rapid Phylogeographic Inference of Regional Epidemic Dynamics for Routine Genomic Surveillance. 译：面向常规基因组监测的区域疫情动力学快速系统地理推断 Res Sq · Lau MS 等 · 2026 10.21203/rs.3.rs-10631496/v1 20. Seroprevalence of varicella antibodies in unvaccinated children with nephrotic syndrome in disease remission. 译：肾病综合征未接种儿童水痘抗体血清阳性率 Indian J Med Res · B B 等 · 2026 10.25259/IJMR_734_2026 其余 1 篇未列出（低影响因子期刊或主题相关度较低）另有 69 篇主题关联较弱或待归类，未列入精选关注公众号「IDepi」，每天 3 分钟，掌握传染病流行病学全球前沿。本速递由 IDepi 编辑部每日汇总产出，内容仅供学术交流，请以期刊原文为准；解读观点仅代表编辑部。

2026-09-09

·野马财经

歌礼制药：重启人生

2018年8月1日，港交所迎来“历史性”时刻。歌礼制药以14港元发行价登陆港股，成为“18A”新规下第一家上市企业，上市初期市值一度达到160亿港元。创始人吴劲梓站在聚光灯下，手中握着的，正是中国首个自主研发的丙型肝炎直接抗病毒药物——戈诺卫。彼时没有人会想到，这家被冠以“中国本土丙肝第一家”之名的企业，会在短短数年内从巅峰跌入谷底，市值一度缩水95%。更让人没有想到的是，绝境中的歌礼制药居然完成一场近乎不可能的重启，彻底转型成为一家聚焦“内分泌”公司。这是一家公司的故事，也是一个时代的寓言。01王座之上歌礼制药的起点，几乎是一个完美的创业故事。2013年12月，吉利德开发出“吉一代”索非布韦（Sovaldi），将丙肝治愈率提升至90%。出色的疗效帮助索非布韦迅速实现放量，上市后的第一个完整年就实现营收102.83亿美元，堪比后来的新冠疫苗。在索非布韦的带动下，丙肝药物成为绝对的行业风口，而吴劲梓则是国内第一批站在风口的人。2013年，吴劲梓在杭州创立歌礼制药，将丙肝药物作为第一个突破口。那时候中国丙肝患者约1000万人，庞大的患者群体意味着可观的市场空间。而吉利德尚未登陆中国市场，丙肝药领域几乎是一片空白。为了抢占先机，吴劲梓选择了一条务实的路径。他曾在接受采访时说：“我们的标准是看开发速度，在确定的疾病领域，哪种方式可以更快地让患者得到所需的药物，我们就采取哪种方式。”因此，歌礼制药在2013年从罗氏引进了达诺瑞韦（戈诺卫），在2014年从美国Presidio公司引进了拉维达韦，共同组成了歌礼制药的抗丙肝药物矩阵。2018年6月13日，戈诺卫顺利获得国家药监局批准上市，成为首个由中国本土企业开发的丙肝直接抗病毒药物，上市半年就实现营收7230万元。歌礼制药走上时代的风口，也顺利迈入港交所的大门。上市当年，歌礼制药就实现营收1.66亿元，净亏损由2017年的5393.5万元大幅收窄至728.5万元，距盈利仅一步之遥。同时，歌礼制药还在2019年代理了上海罗氏的长效干扰素药物派罗欣，再加上临床后期的另一款乙肝药物拉维达韦，歌礼制药的商业化蓝图清晰可见。那是属于歌礼制药的高光时刻。一家中国本土药企，在跨国巨头的环伺中杀出一条血路，成为“18A第一股”，手握首个国产丙肝创新药，并围绕丙肝进行了一系列布局。故事的开篇，就把情节推向了高潮。然而命运最喜欢在一个人最得意的时候，悄悄撤走他脚下的台阶。02时代车轮前，没有捷径虽然戈诺卫顺利成为了首款国产的丙肝药物，但在面对Sovaldi的竞争时，却存在巨大的劣势。戈诺卫属于NS3/4A蛋白酶抑制剂。它的核心劣势在于，必须与长效干扰素（如派罗欣）联合使用。但这种方案不仅需要注射，且干扰素会带来的流感样症状等副作用；而Sovaldi则是首款NS5B聚合酶抑制剂，它最大的突破是实现了丙肝的“全口服”治疗。患者无需再忍受注射干扰素的痛苦，仅需口服药物12周，这彻底改变了丙肝治疗的游戏规则。更为关键的是，吉利德围绕丙肝适应症进行了一系列迭代，先后推出了“吉二代”Harvoni和“吉三代”Epclusa。在持续迭代更新下，Sovaldi自身的销售额已经在2017年骤降至9.64亿美元。图：吉利德丙肝药物矩阵此外，Sovaldi在国内获批的时间为2017年9月，比戈诺卫更早。也就是说，在吉利德这个“魔王”面前，无论是先发优势、迭代能力，还是依从性，歌礼制药全面落于下风。在2019年的医保谈判中，歌礼制药的“戈诺卫方案”意外落选，默沙东的择必达和吉利德的丙通沙（Epclusa）、夏帆宁（Harvoni）以超过85%的降幅进入国家医保乙类目录。当时，歌礼是唯一入围谈判的国产丙肝药，戈诺卫上市初定价238.07元/片，已是进口产品定价的三分之一。然而最终进入目录的，却是两个进口方案。戈诺卫错失医保目录后，歌礼制药营收额由2019年的1.73亿元骤降至2020年的0.35亿元，降幅达惊人的79.8%。更为致命的是，在丙肝口服药物的全面推广的压力下，罗氏决定将派罗欣撤出中国市场，这直接导致歌礼制药的另一营收支柱倒塌。尽管新冠药物利托那韦片在2023年曾带来了短期营收，但歌礼制药实则已然陷入“无药可卖”的境地。曾经歌礼制药描绘的壮美蓝图，如今已经全面破碎。股价成为市场悲观情绪的宣泄口。歌礼制药上市后股价一路下跌，到2024年8月跌至0.76港元的历史低点，市值缩水95%仅约7亿港元。一家曾经市值160亿港元的“18A第一股”，跌到了尘埃里。回看这段坠落，与其说是某一个决策的失误，不如说是一个时代的错位。歌礼在丙肝赛道上面临的，是技术代际的碾压，当全口服、无干扰素成为全球标准时，需要注射的戈诺卫方案已经“过时”。而全口服方案的姗姗来迟，让歌礼失去了唯一的窗口期。在一个存量市场中，迟到的入场券毫无意义。在时代的车轮面前，任何人都没有捷径可走。03废墟上的重建身处绝境中的歌礼制药，在2024年做了一件近乎疯狂的事：公司决定终止病毒性疾病治疗管线，包括慢乙肝、HIV、RSV等在研产品。ASC22（乙肝）、ASC10（呼吸道病毒）、ASC09（HIV）等6个项目相继终止。这一幕已经不能用“壮士断腕”来形容了，歌礼制药几乎砍掉了自己全部的历史。取而代之的，是一个全新的方向——代谢减重赛道。从肝病到减重，从治愈到管理，从存量市场到增量市场——这是一次彻底的范式转换。而推动这一切的，还是创始人吴劲梓。自2022年起，他在公司内部主导推动战略重塑，果断终止前景不明的研发项目，重新聚焦研发具有全球First-in-Class、Best-in-Class潜力的管线。这一次，歌礼制药没有再急于求成，其跳过单靶点多肽类GLP-1药物开发路径，转而聚焦技术门槛更高但潜力更大的方向。图：歌礼制药核心管线目前，歌礼制药的核心管线为ASC30，这是一款每日一次口服小分子GLP-1受体激动剂，能够显著提升患者依从性。2026年公布的II期临床数据显示：125例基线平均体重107.3kg的肥胖受试者，13周治疗时20mg、40mg、60mg维持剂量组经安慰剂校正后的平均体重下降分别达5.4%、7.0%和7.7%，呈剂量依赖性且未出现平台期。而在安全性方面，ASC30展现出显著优于同类药物的胃肠道耐受性，呕吐发生率仅为同滴定方案的礼来orforglipron的一半。但ASC30的真正杀手锏，是它的剂型设计。歌礼同步开发了ASC30的每月一次皮下储库型制剂、每季度一次皮下注射剂型用于体重维持疗法，这在整个GLP-1赛道中是差异化的存在。2026年8月30日，ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药。项目将在美国、欧洲和加拿大入组约4600名肥胖或超重受试者。预计2028年第三季度公布顶线数据，2028年底向FDA提交新药上市申请，2029年初向EMA递交上市许可申请。此外，歌礼制药还构建了一个差异化的代谢管线矩阵，包括超长效GLP-1R/GIPR双靶点多肽ASC35；超长效胰淀素受体激动剂多肽ASC36；口服三靶点多肽ASC37。市场的反应证明了这场豪赌的价值。一年来，歌礼制药股价从2024年8月的0.76港元一度上涨至2025年8月的18.75港元，涨幅超20倍，市值重回百亿港元级别。当然，重启的道路远未平坦。截至2026年6月30日，歌礼持有现金及现金等价物约22.10亿元，可支撑运营至2029年。但2026年上半年研发开支高达3.42亿元，同比增长132.7%，亏损扩大至3.2亿元。核心管线ASC30的数据要到2028年才能读出，这意味着至少还有两年只有投入、没有产出的“烧钱期”。而就在2026年8月31日发布中期业绩的同一天，ASC30的美国化合物专利遭遇石药集团旗下康久普乐发起的PGR挑战。这场专利战的结果，或将直接影响ASC30出海的前景。但无论如何，歌礼已经从废墟中站了起来。它砍掉了自己的过去，在一个全新的战场上重新出发。04创新药启示录歌礼制药的故事，是中国创新药行业的一面镜子，值得后来的药企们借鉴。首先，先发优势不是护城河，技术路线才是。歌礼是中国首个推出丙肝创新药的本土企业，但它输给了技术路线的迭代。当全口服、无干扰素成为全球标准时，需要注射的戈诺卫方案已经过时。在生物医药领域，速度固然重要，但方向比速度更重要。走错路的人，跑得越快，离终点越远。其次，医保准入是创新药的生死线。2019年的医保谈判失利，是歌礼命运转折的起点。对于一个以医院为主要销售渠道的处方药而言，进不了医保就意味着进不了主流市场。戈诺卫在失去医保通道后，销售额从1.24亿跌至110万。第三，差异化是唯一的出路。在GLP-1赛道白热化的竞争中，歌礼制药没有选择做另一个司美格鲁肽或替尔泊肽的跟随者。口服小分子+超长效注射的双剂型设计、每月甚至每季度一次的给药频率——这些差异化的选择，构成了歌礼的核心壁垒。在同质化竞争中，差异化不是加分项，而是生存的前提。最后，18A不是终点，而是起点。歌礼制药作为“18A第一股”，它的浮沉是整个港股18A板块的缩影。从160亿市值到7亿，再从7亿到重回百亿——这条曲线告诉所有创新药企：上市不是故事的结局，而是另一个故事的开始。资本市场的耐心有限，最终能让你活下去的，只有产品本身。歌礼用八年时间完成了一个完整的周期：登顶、坠落、重启。这不是一个关于成功的故事，而是一个关于重生的故事。在生物医药这个行业里，失败是常态，成功是偶然。但比成功更珍贵的，是在失败之后还有勇气重新开始。歌礼制药，正在重启自己的人生。而这场重启的结局，将由2028年的数据来书写。在此之前，所有的掌声和质疑，都只是序章。

2026-09-09

·网易号

歌礼制药：重启人生

2018年8月1日，港交所迎来“历史性”时刻。歌礼制药以14港元发行价登陆港股，成为“18A”新规下第一家上市企业，上市初期市值一度达到160亿港元。创始人吴劲梓站在聚光灯下，手中握着的，正是中国首个自主研发的丙型肝炎直接抗病毒药物——戈诺卫。彼时没有人会想到，这家被冠以“中国本土丙肝第一家”之名的企业，会在短短数年内从巅峰跌入谷底，市值一度缩水95%。更让人没有想到的是，绝境中的歌礼制药居然完成一场近乎不可能的重启，彻底转型成为一家聚焦“内分泌”公司。这是一家公司的故事，也是一个时代的寓言。01王座之上歌礼制药的起点，几乎是一个完美的创业故事。2013年12月，吉利德开发出“吉一代”索非布韦（Sovaldi），将丙肝治愈率提升至90%。出色的疗效帮助索非布韦迅速实现放量，上市后的第一个完整年就实现营收102.83亿美元，堪比后来的新冠疫苗。在索非布韦的带动下，丙肝药物成为绝对的行业风口，而吴劲梓则是国内第一批站在风口的人。2013年，吴劲梓在杭州创立歌礼制药，将丙肝药物作为第一个突破口。那时候中国丙肝患者约1000万人，庞大的患者群体意味着可观的市场空间。而吉利德尚未登陆中国市场，丙肝药领域几乎是一片空白。为了抢占先机，吴劲梓选择了一条务实的路径。他曾在接受采访时说：“我们的标准是看开发速度，在确定的疾病领域，哪种方式可以更快地让患者得到所需的药物，我们就采取哪种方式。”因此，歌礼制药在2013年从罗氏引进了达诺瑞韦（戈诺卫），在2014年从美国Presidio公司引进了拉维达韦，共同组成了歌礼制药的抗丙肝药物矩阵。2018年6月13日，戈诺卫顺利获得国家药监局批准上市，成为首个由中国本土企业开发的丙肝直接抗病毒药物，上市半年就实现营收7230万元。歌礼制药走上时代的风口，也顺利迈入港交所的大门。上市当年，歌礼制药就实现营收1.66亿元，净亏损由2017年的5393.5万元大幅收窄至728.5万元，距盈利仅一步之遥。同时，歌礼制药还在2019年代理了上海罗氏的长效干扰素药物派罗欣，再加上临床后期的另一款乙肝药物拉维达韦，歌礼制药的商业化蓝图清晰可见。那是属于歌礼制药的高光时刻。一家中国本土药企，在跨国巨头的环伺中杀出一条血路，成为“18A第一股”，手握首个国产丙肝创新药，并围绕丙肝进行了一系列布局。故事的开篇，就把情节推向了高潮。然而命运最喜欢在一个人最得意的时候，悄悄撤走他脚下的台阶。02时代车轮前，没有捷径虽然戈诺卫顺利成为了首款国产的丙肝药物，但在面对Sovaldi的竞争时，却存在巨大的劣势。戈诺卫属于NS3/4A蛋白酶抑制剂。它的核心劣势在于，必须与长效干扰素（如派罗欣）联合使用。但这种方案不仅需要注射，且干扰素会带来的流感样症状等副作用；而Sovaldi则是首款NS5B聚合酶抑制剂，它最大的突破是实现了丙肝的“全口服”治疗。患者无需再忍受注射干扰素的痛苦，仅需口服药物12周，这彻底改变了丙肝治疗的游戏规则。更为关键的是，吉利德围绕丙肝适应症进行了一系列迭代，先后推出了“吉二代”Harvoni和“吉三代”Epclusa。在持续迭代更新下，Sovaldi自身的销售额已经在2017年骤降至9.64亿美元。图：吉利德丙肝药物矩阵此外，Sovaldi在国内获批的时间为2017年9月，比戈诺卫更早。也就是说，在吉利德这个“魔王”面前，无论是先发优势、迭代能力，还是依从性，歌礼制药全面落于下风。在2019年的医保谈判中，歌礼制药的“戈诺卫方案”意外落选，默沙东的择必达和吉利德的丙通沙（Epclusa）、夏帆宁（Harvoni）以超过85%的降幅进入国家医保乙类目录。当时，歌礼是唯一入围谈判的国产丙肝药，戈诺卫上市初定价238.07元/片，已是进口产品定价的三分之一。然而最终进入目录的，却是两个进口方案。戈诺卫错失医保目录后，歌礼制药营收额由2019年的1.73亿元骤降至2020年的0.35亿元，降幅达惊人的79.8%。更为致命的是，在丙肝口服药物的全面推广的压力下，罗氏决定将派罗欣撤出中国市场，这直接导致歌礼制药的另一营收支柱倒塌。尽管新冠药物利托那韦片在2023年曾带来了短期营收，但歌礼制药实则已然陷入“无药可卖”的境地。曾经歌礼制药描绘的壮美蓝图，如今已经全面破碎。股价成为市场悲观情绪的宣泄口。歌礼制药上市后股价一路下跌，到2024年8月跌至0.76港元的历史低点，市值缩水95%仅约7亿港元。一家曾经市值160亿港元的“18A第一股”，跌到了尘埃里。回看这段坠落，与其说是某一个决策的失误，不如说是一个时代的错位。歌礼在丙肝赛道上面临的，是技术代际的碾压，当全口服、无干扰素成为全球标准时，需要注射的戈诺卫方案已经“过时”。而全口服方案的姗姗来迟，让歌礼失去了唯一的窗口期。在一个存量市场中，迟到的入场券毫无意义。在时代的车轮面前，任何人都没有捷径可走。03废墟上的重建身处绝境中的歌礼制药，在2024年做了一件近乎疯狂的事：公司决定终止病毒性疾病治疗管线，包括慢乙肝、HIV、RSV等在研产品。ASC22（乙肝）、ASC10（呼吸道病毒）、ASC09（HIV）等6个项目相继终止。这一幕已经不能用“壮士断腕”来形容了，歌礼制药几乎砍掉了自己全部的历史。取而代之的，是一个全新的方向——代谢减重赛道。从肝病到减重，从治愈到管理，从存量市场到增量市场——这是一次彻底的范式转换。而推动这一切的，还是创始人吴劲梓。自2022年起，他在公司内部主导推动战略重塑，果断终止前景不明的研发项目，重新聚焦研发具有全球First-in-Class、Best-in-Class潜力的管线。这一次，歌礼制药没有再急于求成，其跳过单靶点多肽类GLP-1药物开发路径，转而聚焦技术门槛更高但潜力更大的方向。图：歌礼制药核心管线目前，歌礼制药的核心管线为ASC30，这是一款每日一次口服小分子GLP-1受体激动剂，能够显著提升患者依从性。2026年公布的II期临床数据显示：125例基线平均体重107.3kg的肥胖受试者，13周治疗时20mg、40mg、60mg维持剂量组经安慰剂校正后的平均体重下降分别达5.4%、7.0%和7.7%，呈剂量依赖性且未出现平台期。而在安全性方面，ASC30展现出显著优于同类药物的胃肠道耐受性，呕吐发生率仅为同滴定方案的礼来orforglipron的一半。但ASC30的真正杀手锏，是它的剂型设计。歌礼同步开发了ASC30的每月一次皮下储库型制剂、每季度一次皮下注射剂型用于体重维持疗法，这在整个GLP-1赛道中是差异化的存在。2026年8月30日，ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药。项目将在美国、欧洲和加拿大入组约4600名肥胖或超重受试者。预计2028年第三季度公布顶线数据，2028年底向FDA提交新药上市申请，2029年初向EMA递交上市许可申请。此外，歌礼制药还构建了一个差异化的代谢管线矩阵，包括超长效GLP-1R/GIPR双靶点多肽ASC35；超长效胰淀素受体激动剂多肽ASC36；口服三靶点多肽ASC37。市场的反应证明了这场豪赌的价值。一年来，歌礼制药股价从2024年8月的0.76港元一度上涨至2025年8月的18.75港元，涨幅超20倍，市值重回百亿港元级别。当然，重启的道路远未平坦。截至2026年6月30日，歌礼持有现金及现金等价物约22.10亿元，可支撑运营至2029年。但2026年上半年研发开支高达3.42亿元，同比增长132.7%，亏损扩大至3.2亿元。核心管线ASC30的数据要到2028年才能读出，这意味着至少还有两年只有投入、没有产出的“烧钱期”。而就在2026年8月31日发布中期业绩的同一天，ASC30的美国化合物专利遭遇石药集团旗下康久普乐发起的PGR挑战。这场专利战的结果，或将直接影响ASC30出海的前景。但无论如何，歌礼已经从废墟中站了起来。它砍掉了自己的过去，在一个全新的战场上重新出发。04创新药启示录歌礼制药的故事，是中国创新药行业的一面镜子，值得后来的药企们借鉴。首先，先发优势不是护城河，技术路线才是。歌礼是中国首个推出丙肝创新药的本土企业，但它输给了技术路线的迭代。当全口服、无干扰素成为全球标准时，需要注射的戈诺卫方案已经过时。在生物医药领域，速度固然重要，但方向比速度更重要。走错路的人，跑得越快，离终点越远。其次，医保准入是创新药的生死线。2019年的医保谈判失利，是歌礼命运转折的起点。对于一个以医院为主要销售渠道的处方药而言，进不了医保就意味着进不了主流市场。戈诺卫在失去医保通道后，销售额从1.24亿跌至110万。第三，差异化是唯一的出路。在GLP-1赛道白热化的竞争中，歌礼制药没有选择做另一个司美格鲁肽或替尔泊肽的跟随者。口服小分子+超长效注射的双剂型设计、每月甚至每季度一次的给药频率——这些差异化的选择，构成了歌礼的核心壁垒。在同质化竞争中，差异化不是加分项，而是生存的前提。最后，18A不是终点，而是起点。歌礼制药作为“18A第一股”，它的浮沉是整个港股18A板块的缩影。从160亿市值到7亿，再从7亿到重回百亿——这条曲线告诉所有创新药企：上市不是故事的结局，而是另一个故事的开始。资本市场的耐心有限，最终能让你活下去的，只有产品本身。歌礼用八年时间完成了一个完整的周期：登顶、坠落、重启。这不是一个关于成功的故事，而是一个关于重生的故事。在生物医药这个行业里，失败是常态，成功是偶然。但比成功更珍贵的，是在失败之后还有勇气重新开始。歌礼制药，正在重启自己的人生。而这场重启的结局，将由2028年的数据来书写。在此之前，所有的掌声和质疑，都只是序章。

100 项与艾尔巴韦/格拉瑞韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10778	艾尔巴韦/格拉瑞韦	J05AP54	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
丙型肝炎	中国	Merck Sharp & Dohme BV	2018-04-28
慢性丙型肝炎	加拿大	Merck Canada, Inc.	2016-01-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	临床3期	-	Merck Sharp & Dohme Corp.	2019-09-01
纤维化	临床3期	法国	Merck Sharp & Dohme Corp.	2017-01-11
HIV感染	临床3期	-	Merck Sharp & Dohme Corp.	2014-06-03
心脏衰竭	临床2期	美国	Merck Sharp & Dohme Corp.	2017-05-16
终末期肾脏病	临床2期	美国	Merck Sharp & Dohme Corp.	2016-05-01
慢性丙型肝炎基因型 3	临床2期	-	Merck Sharp & Dohme Corp.	2014-06-13
慢性丙型肝炎基因型 1	临床阶段不明	-	Merck Sharp & Dohme Corp.	2017-05-01
不可切除的肝细胞癌	临床阶段不明	-	Merck Sharp & Dohme Corp.	2017-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02940496 (CTgov)	临床2期	非小细胞肺癌IIIA期 \| 晚期肝细胞癌 \| 丙型肝炎 ... 更多	15	Pembrolizumab ("ARM A Pembrolizumab (Q3W)")	鏇鬱顧窪簾觸鑰築蓋鏇(範窪醖鑰範願齋糧簾願) = 糧艱夢鬱夢艱餘製鏇鹹鏇製遞憲餘網鏇壓壓顧 (餘繭鑰膚蓋鏇願齋淵淵, 網齋製積艱選簾醖鹹膚 ~ 簾膚蓋膚觸蓋糧願艱鹽) 更多	-	2025-07-15
				Elbasvir+Grazoprevir+Pembrolizumab ("ARM B Pembrolizumab (Q3W)+Grazoprevir (qd x 12 Weeks)+Elbasvir (QD x 12 Weeks")	獵鹽顧餘齋糧艱製鏇憲(鹽鹹衊積製鬱鑰鏇壓淵) = 鹹鹽鑰觸願襯膚獵簾膚襯選糧選積獵襯憲艱廠 (壓鏇蓋糧艱膚鏇顧鑰壓, 壓齋鬱膚窪鑰選鏇鬱齋 ~ 鏇積膚顧蓋鏇鑰廠窪繭) 更多
NCT02743897 (THINKER, CTgov)	临床1/2期	终末期肾脏病 \| 丙型肝炎	62	Mavyret+Zepatier	範鑰窪獵鬱獵醖糧選淵 = 壓選醖鹹蓋鏇遞鹹製獵糧衊顧鑰遞獵鹹顧鬱製 (鏇遞窪襯鬱廠蓋齋憲壓, 範鏇築築糧艱餘遞壓窪 ~ 鑰齋願蓋獵鹹餘鏇衊餘) 更多	-	2023-06-15
NCT03823911 (CHROME, CTgov)	临床4期	心血管疾病 \| HIV感染 \| 丙型肝炎	87	Cardiac MRI+Elbasvir / Grazoprevir Oral Tablet [Zepatier] (Hepatitis C Mono-Infected)	蓋膚膚鹽壓鏇壓襯遞選(齋觸窪鏇艱築糧構窪觸) = 廠積淵鹹鬱製製構鏇鏇糧觸願夢艱齋蓋鹽衊醖 (簾觸獵顧網遞簾淵夢願, 0.96) 更多	-	2023-05-22
				Cardiac MRI+Elbasvir / Grazoprevir Oral Tablet [Zepatier] (HIV and Hepatitis C Co-Infected)	蓋膚膚鹽壓鏇壓襯遞選(齋觸窪鏇艱築糧構窪觸) = 遞繭壓觸構醖鬱淵願鹽糧觸願夢艱齋蓋鹽衊醖 (簾觸獵顧網遞簾淵夢願, 0) 更多
NCT03724149 (SHELTER, CTgov)	临床1/2期	丙型肝炎	10	Epclusa+Zepatier	鑰壓壓積壓積鹹淵糧衊 = 醖顧蓋繭顧鏇夢範艱壓繭願廠艱鏇構觸壓鹹窪 (蓋鹽願製廠築構艱糧鹹, 餘衊遞鬱廠窪窪壓顧獵 ~ 廠選鏇壓襯齋膚構艱願) 更多	-	2023-04-14
NCT03578640 (ELEGANT-4, DDW2022)	临床3期	丙型肝炎	30	Elbasvir/Grazoprevir	餘憲衊範餘窪窪壓蓋構(獵蓋繭願蓋糧醖憲憲顧) = 廠糧繭壓範鏇淵餘築餘遞簾築淵膚餘憲簾顧廠 (網衊鏇獵築襯窪醖構鬱, 90 ~ 100) 更多	积极	2022-05-21
NCT03578640 (ELEGANT-4, Pubmed)	临床3期	丙型肝炎	30	Elbasvir/Grazoprevir fixed-dose combination	繭範鬱範淵積膚選餘範(製鏇艱窪觸鏇憲觸鑰廠) = 壓醖構壓構製鹹鹽淵製鹽醖製觸顧醖夢積憲鬱 (觸築繭憲簾憲鹹選繭選, 90 ~ 100) 更多	积极	2022-02-09
NCT03365635 (HD, CTgov)	临床4期	丙型肝炎 \| 交叉感染	6	Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] (Genotype 1a -Rx Naive -no NS5A Polymorph)	願繭觸壓築膚蓋壓醖繭 = 膚淵淵壓願網艱窪膚鹽醖蓋膚壓選淵窪遞齋繭 (鹽餘觸艱襯壓糧窪繭構, 願齋蓋壓艱窪觸艱廠窪 ~ 鑰顧鏇糧糧夢願範膚憲) 更多	-	2021-12-15
				Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] (Genotype 1a, Rx Naive + NS5A Polymorph)	願繭觸壓築膚蓋壓醖繭 = 獵獵夢築夢簾廠鑰淵構醖蓋膚壓選淵窪遞齋繭 (鹽餘觸艱襯壓糧窪繭構, 蓋構淵糧繭憲獵齋簾衊 ~ 簾簾憲選淵憲願襯觸顧) 更多
NCT03093415 (CTgov)	临床4期	物质滥用 \| 丙型肝炎	100	elbasvir-grazoprevir (50 mg/100 mg) (Old Town Clinic, Medication Assisted Therapy Group)	糧壓網觸選觸構鹹憲衊 = 艱鑰繭願憲築窪構襯繭積窪壓糧繭鹽築積鬱艱 (襯遞積淵積顧鑰憲鏇積, 齋廠觸築壓築醖簾積積 ~ 築齋餘壓襯蓋網糧製壓) 更多	-	2020-11-12
				elbasvir-grazoprevir (50 mg/100 mg) (Outside In Clinic, Needle Exchange Program)	糧壓網觸選觸構鹹憲衊 = 壓齋窪憲鹹憲衊鬱窪鬱積窪壓糧繭鹽築積鬱艱 (襯遞積淵積顧鑰憲鏇積, 廠醖網構鑰壓鹹衊膚淵 ~ 蓋壓鬱簾齋齋窪選鹽鑰) 更多
NCT02973503 (STREAGER, CTgov)	临床3期	纤维化 \| 慢性丙型肝炎	117	Elbasvir/Grazoprevir Fixed Dose Combination	齋顧憲夢齋蓋觸蓋選廠 = 範鹽夢夢範簾膚鑰蓋鬱範觸蓋製網窪膚網醖製 (選襯鏇簾鹽窪積壓蓋膚, 構齋艱觸鑰蓋積餘壓壓 ~ 壓鬱窪壓夢積築鬱廠憲) 更多	-	2020-09-07
German hepatitis C-registry (DHC-R) (EASL2020)	N/A	慢性肾病	-	Grazoprevir/elbasvir (EBR/GZR)	蓋網淵膚築壓壓願築製(獵壓鬱憲選遞壓願繭獵) = 網鬱觸衊窪觸鹹壓膚獵構製壓鏇築構憲繭鏇糧 (醖構蓋襯衊鹹鬱廠壓願 ) 更多	积极	2020-08-27
				Grazoprevir/elbasvir + ribavirin (EBR/GZR + ribavirin)	蓋網淵膚築壓壓願築製(獵壓鬱憲選遞壓願繭獵) = 廠網夢觸憲夢窪襯齋餘構製壓鏇築構憲繭鏇糧 (醖構蓋襯衊鹹鬱廠壓願 ) 更多